Gene: Bcl2l1 (Bcl2-like 1)  Rattus norvegicus Symbol: Bcl2l1 Name: Bcl2-like 1 Description: ENCODES a protein that exhibits BH domain binding; cysteine-type endopeptidase inhibitor activity involved in apoptotic process; MDM2/MDM4 family protein binding; INVOLVED IN apoptotic process; negative regulation of apoptotic process; negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; PARTICIPATES IN intrinsic apoptotic pathway; erythropoietin signaling pathway; interleukin-3 signaling pathway; ASSOCIATED WITH Brain Ischemia; Diabetes Mellitus, Experimental; Erectile Dysfunction; FOUND IN mitochondrial envelope; mitochondrial outer membrane; Bcl-2 family protein complex (ortholog); INTERACTS WITH (+)-alpha-tocopherol; (R)-carnitine; (R)-mevalonic acid Type: protein-coding RefSeq Status: VALIDATED Also known as: apoptosis regulator Bcl-X; B cell lymphoma 2 like; B cell lymphoma like X; bcl-2-like protein 1; bcl-X; Bcl-xl; bcl2-L-1; Bcl2l; Bclx Orthologs: Homo sapiens : BCL2L1 (BCL2-like 1)  HGNC Mus musculus : Bcl2l1 (BCL2-like 1)  MGI Related Pseudogenes: Bcl2l1-ps1   Latest Assembly: RGSC Genome Assembly v3.4 Position: Map Chr Position Strand Source Rat Cytogenetic Map 3 q41.2   NCBI RGSC Genome Assembly v5.0 3 154,662,586 - 154,716,802 - NCBI RGSC Genome Assembly v3.4 3 143,129,087 - 143,180,199 - NCBI Rat Celera Assembly 3 140,002,906 - 140,053,959 - NCBI Genome Assembly 3.1 3 143,082,602 - 143,084,431 - NCBI Model Launch Genome Browser (GBrowse) Annotation    (Toggle Detail/Summary View) Disease Annotations Term Qualifier Evidence With Reference Notes Source Original Reference(s) Brain Ischemia   IEP   1643491 protein:increased expression:cerebral cortex RGD   Breast Neoplasms   ISS RGD:735516 1643481   RGD   Breast Neoplasms   ISS RGD:735516 1643480   RGD   Breast Neoplasms   ISS RGD:735516 1643478   RGD   Carcinoma, Renal Cell   ISS RGD:735516 1643483   RGD   Carcinoma, Transitional Cell   ISS RGD:735516 1643477   RGD   Diabetes Mellitus, Experimental   IED ] 2292685 protein:decreased expression, altered activity:testis RGD   Endometrial Neoplasms   ISS RGD:735516 1643476 protein:increased expression:endometrium RGD   Erectile Dysfunction   IED   1579980   RGD   Leiomyoma   ISS RGD:735516 1643479 associated with Carcinoma, Renal Cell;protein:increased expression:myometrium RGD   Myocardial Infarction   IPM   1643494   RGD   Ocular Hypertension   IEP   1643493 mRNA:increased expression:retina RGD   Ovarian Neoplasms   ISS RGD:735516 1643478   RGD   Prostatic Neoplasms   ISS RGD:735516 1643474   RGD   Shock, Hemorrhagic   IEP   1643525 protein:increased expression:liver, mitochondrion RGD   Urinary Bladder Neoplasms Disease_progression ISS RGD:735516 2292910   RGD   Uterine Cervical Neoplasms   ISS RGD:735516 1643476 protein:increased expression:uterine cervix RGD   Uterine Neoplasms   ISS RGD:735516 1643479 associated with Carcinoma, Renal Cell;protein:increased expression:uterus RGD   Wilms Tumor Disease_progression ISS RGD:735516 1643482   RGD   Gene-Chemical Interaction Annotations Term Qualifier Evidence With Reference Notes Source Original Reference(s) (+)-alpha-tocopherol decreases expression EXP   6480464 alpha-Tocopherol results in decreased expression of BCL2L1 protein CTD PMID:18942769 (-)-epigallocatechin 3-gallate multiple interactions ISO RGD:735516 6480464 calyculin A inhibits the reaction [[Ibuprofen co-treated with epigallocatechin gallate] results in decreased expression of BCL2L1 mRNA alternative form]; more ... CTD PMID:18348186 (-)-epigallocatechin 3-gallate multiple interactions ISO RGD:735516 6480464 [arsenic trioxide co-treated with epigallocatechin gallate] results in decreased expression of BCL2L1 protein CTD PMID:20950636 (R)-carnitine multiple interactions EXP   6480464 Carnitine inhibits the reaction [Gentamicins results in decreased expression of BCL2L1 protein] CTD PMID:19491382 (R)-mevalonic acid multiple interactions EXP   6480464 Mevalonic Acid inhibits the reaction [Lovastatin results in decreased expression of BCL2L1 protein] CTD PMID:11178870 (R)-noradrenaline decreases expression EXP   6480464 Norepinephrine results in decreased expression of BCL2L1 mRNA CTD PMID:18675472 (S)-amphetamine affects expression EXP   6480464 Dextroamphetamine affects the expression of BCL2L1 mRNA alternative form CTD PMID:10336889 (S)-colchicine multiple interactions EXP   6480464 [Diethylnitrosamine co-treated with Colchicine] results in decreased expression of BCL2L1 protein CTD PMID:11749691 (S)-nicotine multiple interactions ISO RGD:1552009 6480464 resveratrol inhibits the reaction [Nicotine results in decreased expression of BCL2L1 mRNA] CTD PMID:22687363 (S)-nicotine decreases expression ISO RGD:1552009 6480464 Nicotine results in decreased expression of BCL2L1 mRNA CTD PMID:22687363 1'-acetoxychavicol acetate multiple interactions ISO RGD:735516 6480464 1'-acetoxychavicol acetate inhibits the reaction [TNF protein results in increased expression of BCL2L1 protein] CTD PMID:15905586 1,3-dinitrobenzene decreases response to substance ISO RGD:735516 6480464 BCL2L1 protein results in decreased susceptibility to 3-dinitrobenzene CTD PMID:10960601 1,3-dinitrobenzene decreases expression EXP   6480464 3-dinitrobenzene results in decreased expression of BCL2L1 mRNA CTD PMID:22841810 1,3-dinitrobenzene increases expression EXP   6480464 3-dinitrobenzene results in increased expression of BCL2L1 mRNA CTD PMID:16025311 1,3-dinitrobenzene affects response to substance EXP   6480464 BCL2L1 protein affects the susceptibility to 3-dinitrobenzene CTD PMID:16257055 17beta-estradiol affects expression ISO RGD:735516 6480464 Estradiol affects the expression of BCL2L1 mRNA CTD PMID:11896290 17beta-estradiol decreases expression ISO RGD:735516 6480464 Estradiol results in decreased expression of BCL2L1 mRNA CTD PMID:21632981 17beta-estradiol increases expression ISO RGD:735516 6480464 Estradiol results in increased expression of BCL2L1 mRNA CTD PMID:15969986 PMID:19698761 17beta-estradiol multiple interactions EXP   6480464 Estradiol inhibits the reaction [Dimethylnitrosamine results in decreased expression of BCL2L1 protein] CTD PMID:14659978 17beta-estradiol increases expression ISO RGD:735516 6480464 Estradiol results in increased expression of BCL2L1 protein CTD PMID:15969986 17beta-estradiol increases expression ISO RGD:735516 6480464 Estradiol results in increased expression of BCL2L1 mRNA CTD PMID:19698761 PMID:15969986 17beta-hydroxy-5alpha-androstan-3-one increases expression ISO RGD:1552009 6480464 Dihydrotestosterone results in increased expression of BCL2L1 mRNA CTD PMID:17023530 17beta-hydroxy-5alpha-androstan-3-one multiple interactions EXP   6480464 Dihydrotestosterone inhibits the reaction [Dehydroepiandrosterone results in increased expression of BCL2L1 protein] CTD PMID:16407456 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:735516 6480464 Tetrachlorodibenzodioxin results in decreased expression of BCL2L1 mRNA CTD PMID:16039398 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:735516 6480464 Tetrachlorodibenzodioxin affects the expression of BCL2L1 mRNA CTD PMID:22574217 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:1552009 6480464 Tetrachlorodibenzodioxin affects the expression of BCL2L1 mRNA CTD PMID:21570461 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:1552009 6480464 Tetrachlorodibenzodioxin results in increased expression of BCL2L1 mRNA CTD PMID:12167310 PMID:14718646 2,3,7,8-tetrachlorodibenzodioxine increases expression EXP   6480464 Tetrachlorodibenzodioxin results in increased expression of BCL2L1 protein; more ... CTD PMID:15965093 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:1552009 6480464 Tetrachlorodibenzodioxin results in increased expression of BCL2L1 mRNA CTD PMID:14718646 PMID:12167310 2,3,7,8-tetrachlorodibenzodioxine decreases expression EXP   6480464 Tetrachlorodibenzodioxin results in decreased expression of BCL2L1 mRNA; more ... CTD PMID:15965093 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:1552009 6480464 Tetrachlorodibenzodioxin results in decreased expression of BCL2L1 mRNA CTD PMID:19933214 2,4-dinitrotoluene affects expression EXP   6480464 2,4-dinitrotoluene affects the expression of BCL2L1 mRNA CTD PMID:21346803 2,6-dichloroindophenol multiple interactions ISO RGD:735516 6480464 [2,6-Dichloroindophenol co-treated with NQO1 protein polymorphism] results in decreased expression of BCL2L1 mRNA CTD PMID:21034357 2-acetamidofluorene multiple interactions EXP   6480464 [Diethylnitrosamine co-treated with 2-Acetylaminofluorene] affects the expression of BCL2L1 protein; more ... CTD PMID:11915028 2-acetamidofluorene increases expression ISO RGD:1552009 6480464 2-Acetylaminofluorene results in increased expression of BCL2L1 mRNA CTD PMID:21607683 2-amino-2-deoxy-D-glucopyranose decreases expression ISO RGD:735516 6480464 Glucosamine results in decreased expression of BCL2L1 protein CTD PMID:15972124 2-amino-2-deoxy-D-glucopyranose decreases expression ISO RGD:735516 6480464 Glucosamine results in decreased expression of BCL2L1 protein CTD PMID:16850161 PMID:15972124 2-amino-2-deoxy-D-glucopyranose multiple interactions ISO RGD:735516 6480464 pepstatin inhibits the reaction [Glucosamine results in decreased expression of BCL2L1 protein] CTD PMID:16850161 2-amino-2-deoxy-D-glucopyranose decreases expression ISO RGD:735516 6480464 Glucosamine results in decreased expression of BCL2L1 protein CTD PMID:15972124 PMID:16850161 2-deoxy-D-glucose decreases response to substance ISO RGD:1552009 6480464 BCL2L1 protein results in decreased susceptibility to Deoxyglucose CTD PMID:10679475 2-ethoxyethanol increases expression EXP   6480464 2-ethoxyethanol results in increased expression of BCL2L1 mRNA CTD PMID:19643169 2-methoxyethanol increases expression EXP   6480464 methyl cellosolve results in increased expression of BCL2L1 mRNA CTD PMID:19643169 3'-amino-3'-deoxy-N(6),N(6)-dimethyladenosine multiple interactions EXP   6480464 Dinoprostone affects the reaction [Puromycin Aminonucleoside results in decreased expression of BCL2L1 protein] CTD PMID:16396944 3'-amino-3'-deoxy-N(6),N(6)-dimethyladenosine multiple interactions ISO RGD:1552009 6480464 [Puromycin Aminonucleoside co-treated with pifithrin] results in increased expression of BCL2L1 protein; more ... CTD PMID:15987750 3'-amino-3'-deoxy-N(6),N(6)-dimethyladenosine decreases expression EXP   6480464 Puromycin Aminonucleoside results in decreased expression of BCL2L1 protein CTD PMID:16396944 3'-amino-3'-deoxy-N(6),N(6)-dimethyladenosine decreases expression ISO RGD:1552009 6480464 Puromycin Aminonucleoside results in decreased expression of BCL2L1 protein CTD PMID:15987750 3,3',5-triiodo-L-thyronine increases expression ISO RGD:735516 6480464 Triiodothyronine results in increased expression of BCL2L1 protein CTD PMID:16021636 3,3',5-triiodo-L-thyronine increases expression EXP   6480464 Triiodothyronine results in increased expression of BCL2L1 protein CTD PMID:16021636 3,3'-diindolylmethane increases expression ISO RGD:735516 6480464 3,3'-diindolylmethane results in increased expression of BCL2L1 mRNA; more ... CTD PMID:18025290 3,4-methylenedioxymethamphetamine affects expression EXP   6480464 N-Methyl-3,4-methylenedioxyamphetamine affects the expression of BCL2L1 mRNA alternative form CTD PMID:10336889 3-methyladenine multiple interactions ISO RGD:1552009 6480464 3-methyladenine inhibits the reaction [Fluorouracil results in increased expression of BCL2L1 protein] CTD PMID:19116755 3-methyladenine increases expression ISO RGD:1552009 6480464 3-methyladenine results in increased expression of BCL2L1 mRNA CTD PMID:21681844 3-methyladenine multiple interactions ISO RGD:735516 6480464 3-methyladenine inhibits the reaction [Fluorouracil results in increased expression of BCL2L1 protein] CTD PMID:19116755 3-nitropropanoic acid decreases expression EXP   6480464 3-nitropropionic acid results in decreased expression of BCL2L1 mRNA CTD PMID:21827809 3-nitropropanoic acid multiple interactions EXP   6480464 Ginkgo biloba extract 761 inhibits the reaction [3-nitropropionic acid results in decreased expression of BCL2L1 mRNA] CTD PMID:21827809 4-hydroxynon-2-enal decreases expression ISO RGD:1552009 6480464 4-hydroxy-2-nonenal results in decreased expression of BCL2L1 mRNA CTD PMID:19191707 4-hydroxynon-2-enal decreases expression ISO RGD:735516 6480464 4-hydroxy-2-nonenal results in decreased expression of BCL2L1 mRNA CTD PMID:12419474 4-hydroxyphenyl retinamide multiple interactions ISO RGD:735516 6480464 [Fenretinide co-treated with Carmustine] results in decreased expression of BCL2L1 protein CTD PMID:16187019 4-hydroxyphenyl retinamide decreases expression ISO RGD:735516 6480464 Fenretinide results in decreased expression of BCL2L1 protein CTD PMID:16187019 4-vinylcyclohexene dioxide increases expression ISO RGD:1552009 6480464 4-vinyl-1-cyclohexene dioxide results in increased expression of BCL2L1 mRNA CTD PMID:20829426 5-aza-2'-deoxycytidine multiple interactions ISO RGD:735516 6480464 [decitabine co-treated with Depsipeptides] results in decreased expression of BCL2L1 mRNA CTD PMID:17064661 5-aza-2'-deoxycytidine decreases expression ISO RGD:735516 6480464 decitabine results in decreased expression of BCL2L1 protein CTD PMID:19372550 5-azacytidine multiple interactions ISO RGD:735516 6480464 [metacept-1 co-treated with Azacitidine] results in decreased expression of BCL2L1 CTD PMID:19148494 5-azacytidine affects expression ISO RGD:735516 6480464 [Azacitidine affects the expression of IL6R protein] which affects the expression of BCL2L1 protein CTD PMID:18443271 5-fluorouracil decreases expression ISO RGD:1552009 6480464 Fluorouracil results in decreased expression of BCL2L1 protein CTD PMID:20844880 5-fluorouracil affects response to substance ISO RGD:735516 6480464 BCL2L1 protein affects the susceptibility to Fluorouracil CTD PMID:15767554 more ... 5-fluorouracil affects response to substance ISO RGD:735516 6480464 BCL2L1 protein affects the susceptibility to Fluorouracil CTD PMID:15767554 more ... 5-fluorouracil decreases expression ISO RGD:735516 6480464 Fluorouracil results in decreased expression of BCL2L1 mRNA CTD PMID:17045692 PMID:21474236 5-fluorouracil affects response to substance ISO RGD:735516 6480464 BCL2L1 protein affects the susceptibility to Fluorouracil CTD PMID:17033717 more ... 5-fluorouracil affects response to substance ISO RGD:735516 6480464 BCL2L1 protein affects the susceptibility to Fluorouracil CTD PMID:17033717 more ... 5-fluorouracil multiple interactions ISO RGD:1552009 6480464 3-methyladenine inhibits the reaction [Fluorouracil results in increased expression of BCL2L1 protein] CTD PMID:19116755 5-fluorouracil multiple interactions ISO RGD:735516 6480464 IFNA1 promotes the reaction [Fluorouracil results in decreased expression of BCL2L1 mRNA] CTD PMID:21474236 5-fluorouracil multiple interactions ISO RGD:735516 6480464 gemcitabine inhibits the reaction [Fluorouracil affects the expression of BCL2L1 protein]; more ... CTD PMID:16929163 5-fluorouracil increases expression ISO RGD:735516 6480464 Fluorouracil results in increased expression of BCL2L1 protein CTD PMID:19116755 5-fluorouracil increases expression ISO RGD:735516 6480464 Fluorouracil results in increased expression of BCL2L1 mRNA CTD PMID:16557594 5-fluorouracil decreases expression ISO RGD:735516 6480464 Fluorouracil results in decreased expression of BCL2L1 protein CTD PMID:17399942 5-fluorouracil decreases expression ISO RGD:735516 6480464 Fluorouracil results in decreased expression of BCL2L1 CTD PMID:12442003 5-fluorouracil decreases expression ISO RGD:735516 6480464 Fluorouracil results in decreased expression of BCL2L1 mRNA CTD PMID:21474236 PMID:17045692 5-fluorouracil multiple interactions ISO RGD:735516 6480464 [Fluorouracil co-treated with IFNA1 protein] results in decreased expression of BCL2L1 mRNA CTD PMID:17045692 5-fluorouracil multiple interactions ISO RGD:735516 6480464 [Fluorouracil co-treated with RNF34 protein] results in increased expression of BCL2L1 protein CTD PMID:16596200 5-fluorouracil affects expression ISO RGD:735516 6480464 Fluorouracil affects the expression of BCL2L1 mRNA; more ... CTD PMID:16929163 5-fluorouracil decreases response to substance ISO RGD:735516 6480464 BCL2L1 protein results in decreased susceptibility to Fluorouracil CTD PMID:17439414 5-fluorouracil multiple interactions ISO RGD:735516 6480464 BCL2L1 protein inhibits the reaction [BID protein results in increased susceptibility to Fluorouracil] CTD PMID:15289866 5-fluorouracil multiple interactions ISO RGD:735516 6480464 BAY 11-7085 inhibits the reaction [[Fluorouracil co-treated with RNF34 protein] results in increased expression of BCL2L1 mRNA] CTD PMID:16407826 5-fluorouracil affects response to substance ISO RGD:735516 6480464 BCL2L1 protein affects the susceptibility to Fluorouracil CTD PMID:16875599 more ... 5-fluorouracil multiple interactions ISO RGD:735516 6480464 3-methyladenine inhibits the reaction [Fluorouracil results in increased expression of BCL2L1 protein] CTD PMID:19116755 5-fluorouracil multiple interactions ISO RGD:1552009 6480464 IL1RN protein inhibits the reaction [Fluorouracil results in decreased expression of BCL2L1 protein] CTD PMID:20844880 5-fluorouracil increases expression ISO RGD:1552009 6480464 Fluorouracil results in increased expression of BCL2L1 protein CTD PMID:19116755 acetylsalicylic acid decreases expression ISO RGD:1552009 6480464 Aspirin results in decreased expression of BCL2L1 protein CTD PMID:20886344 acetylsalicylic acid increases expression ISO RGD:735516 6480464 Aspirin results in increased expression of BCL2L1 mRNA CTD PMID:17342322 PMID:20457246 acetylsalicylic acid increases expression ISO RGD:735516 6480464 Aspirin results in increased expression of BCL2L1 mRNA CTD PMID:20457246 PMID:17342322 actinomycin D decreases expression ISO RGD:735516 6480464 Dactinomycin results in decreased expression of BCL2L1 protein CTD PMID:15592511 actinomycin D multiple interactions ISO RGD:735516 6480464 Dexamethasone inhibits the reaction [Dactinomycin results in increased expression of BCL2L1 protein] CTD PMID:9326359 actinomycin D increases expression ISO RGD:735516 6480464 Dactinomycin results in increased expression of BCL2L1 protein alternative form CTD PMID:12430140 actinomycin D increases expression ISO RGD:735516 6480464 Dactinomycin results in increased expression of BCL2L1 protein CTD PMID:9326359 adenosine decreases expression ISO RGD:735516 6480464 Adenosine results in decreased expression of BCL2L1 mRNA; more ... CTD PMID:20063052 adenosine multiple interactions ISO RGD:735516 6480464 Dipyridamole inhibits the reaction [Adenosine results in decreased expression of BCL2L1 mRNA]; more ... CTD PMID:20063052 afimoxifene increases expression ISO RGD:735516 6480464 4-hydroxytamoxifen results in increased expression of BCL2L1 mRNA CTD PMID:19698761 aflatoxin B1 increases expression ISO RGD:735516 6480464 Aflatoxin B1 results in increased expression of BCL2L1 mRNA CTD PMID:22100608 aldehydo-D-glucosamine decreases expression ISO RGD:735516 6480464 Glucosamine results in decreased expression of BCL2L1 protein CTD PMID:15972124 aldehydo-D-glucosamine decreases expression ISO RGD:735516 6480464 Glucosamine results in decreased expression of BCL2L1 protein CTD PMID:16850161 PMID:15972124 aldehydo-D-glucosamine multiple interactions ISO RGD:735516 6480464 pepstatin inhibits the reaction [Glucosamine results in decreased expression of BCL2L1 protein] CTD PMID:16850161 aldehydo-D-glucosamine decreases expression ISO RGD:735516 6480464 Glucosamine results in decreased expression of BCL2L1 protein CTD PMID:15972124 PMID:16850161 all-trans-retinoic acid multiple interactions ISO RGD:735516 6480464 leptomycin B inhibits the reaction [Tretinoin results in decreased expression of BCL2L1 protein] CTD PMID:14592536 all-trans-retinoic acid increases expression ISO RGD:1552009 6480464 Tretinoin results in increased expression of BCL2L1 mRNA CTD PMID:22498432 all-trans-retinoic acid decreases expression ISO RGD:735516 6480464 Tretinoin results in decreased expression of BCL2L1 protein CTD PMID:16135400 more ... all-trans-retinoic acid decreases expression ISO RGD:735516 6480464 Tretinoin results in decreased expression of BCL2L1 protein CTD PMID:14592536 more ... all-trans-retinoic acid decreases expression ISO RGD:735516 6480464 Tretinoin results in decreased expression of BCL2L1 protein CTD PMID:14592536 more ... all-trans-retinoic acid affects expression ISO RGD:1552009 6480464 Tretinoin affects the expression of BCL2L1 mRNA CTD PMID:16211290 all-trans-retinoic acid increases expression ISO RGD:735516 6480464 Tretinoin results in increased expression of BCL2L1 protein CTD PMID:10750663 all-trans-retinoic acid decreases expression ISO RGD:735516 6480464 Tretinoin results in decreased expression of BCL2L1 protein CTD PMID:16135400 more ... aluminium oxide increases expression ISO RGD:735516 6480464 Aluminum Oxide analog results in increased expression of BCL2L1 mRNA CTD PMID:23132795 ammonium chloride affects expression EXP   6480464 Ammonium Chloride affects the expression of BCL2L1 mRNA CTD PMID:16483693 ammonium chloride increases expression EXP   6480464 Ammonium Chloride results in increased expression of BCL2L1 protein CTD PMID:16483693 arachidonic acid multiple interactions ISO RGD:735516 6480464 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein]; more ... CTD PMID:19540902 arachidonic acid decreases expression ISO RGD:735516 6480464 Arachidonic Acid results in decreased expression of BCL2L1 protein CTD PMID:19540902 PMID:19720122 arachidonic acid multiple interactions ISO RGD:735516 6480464 [Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2L1 protein; more ... CTD PMID:19620254 arachidonic acid decreases expression ISO RGD:735516 6480464 Arachidonic Acid results in decreased expression of BCL2L1 protein CTD PMID:19540902 arsenic atom increases expression ISO RGD:735516 6480464 Arsenic results in increased expression of BCL2L1 mRNA CTD PMID:19962721 arsenic atom increases expression EXP   6480464 Arsenic results in increased expression of BCL2L1 protein CTD PMID:11756236 atrazine multiple interactions ISO RGD:1552009 6480464 [Atrazine co-treated with Chlorpyrifos co-treated with Endosulfan] results in increased expression of BCL2L1 protein CTD PMID:22515965 atrazine increases expression ISO RGD:1552009 6480464 Atrazine results in increased expression of BCL2L1 protein CTD PMID:22515965 azadirachtin A decreases expression ISO RGD:735516 6480464 azadirachtin results in decreased expression of BCL2L1 mRNA CTD PMID:20429769 azathioprine decreases expression ISO RGD:735516 6480464 Azathioprine results in decreased expression of BCL2L1 mRNA; more ... CTD PMID:12697733 benzene multiple interactions EXP   6480464 [Benzene co-treated with methylmercury II co-treated with Trichloroethylene] results in increased expression of BCL2L1 mRNA CTD PMID:17905399 benzo[a]pyrene increases expression ISO RGD:1552009 6480464 Benzo(a)pyrene results in increased expression of BCL2L1 mRNA CTD PMID:21569818 PMID:18656336 benzo[a]pyrene increases expression ISO RGD:1552009 6480464 Benzo(a)pyrene results in increased expression of BCL2L1 mRNA CTD PMID:18656336 more ... benzo[a]pyrene decreases expression ISO RGD:735516 6480464 Benzo(a)pyrene results in decreased expression of BCL2L1 mRNA CTD PMID:20106945 PMID:21632981 benzo[a]pyrene increases expression ISO RGD:1552009 6480464 Benzo(a)pyrene results in increased expression of BCL2L1 mRNA CTD PMID:18656336 PMID:21569818 benzo[a]pyrene decreases expression ISO RGD:735516 6480464 Benzo(a)pyrene results in decreased expression of BCL2L1 protein CTD PMID:15698582 benzo[a]pyrene increases expression ISO RGD:1552009 6480464 Benzo(a)pyrene results in increased expression of BCL2L1 mRNA CTD PMID:18656336 benzo[a]pyrene multiple interactions ISO RGD:1552009 6480464 [Benzo(a)pyrene co-treated with XPA gene mutant form co-treated with TRP53 gene mutant form] results in decreased expression of BCL2L1 mRNA CTD PMID:21715664 benzo[a]pyrene decreases expression ISO RGD:735516 6480464 Benzo(a)pyrene results in decreased expression of BCL2L1 mRNA CTD PMID:20106945 benzo[b]fluoranthene increases expression ISO RGD:735516 6480464 benzo(b)fluoranthene results in increased expression of BCL2L1 protein CTD PMID:21776270 berberine decreases expression ISO RGD:735516 6480464 Berberine results in decreased expression of BCL2L1 protein CTD PMID:16505103 beta-D-glucosamine decreases expression ISO RGD:735516 6480464 Glucosamine results in decreased expression of BCL2L1 protein CTD PMID:15972124 beta-D-glucosamine decreases expression ISO RGD:735516 6480464 Glucosamine results in decreased expression of BCL2L1 protein CTD PMID:16850161 PMID:15972124 beta-D-glucosamine multiple interactions ISO RGD:735516 6480464 pepstatin inhibits the reaction [Glucosamine results in decreased expression of BCL2L1 protein] CTD PMID:16850161 beta-D-glucosamine decreases expression ISO RGD:735516 6480464 Glucosamine results in decreased expression of BCL2L1 protein CTD PMID:15972124 PMID:16850161 bilirubin multiple interactions ISO RGD:1552009 6480464 Bilirubin promotes the reaction [Iron-Dextran Complex results in increased expression of BCL2L1 protein] CTD PMID:20709802 biochanin A decreases expression ISO RGD:735516 6480464 biochanin A results in decreased expression of BCL2L1 protein CTD PMID:12791511 bisphenol A multiple interactions ISO RGD:735516 6480464 bisphenol A promotes the reaction [Doxorubicin results in increased expression of BCL2L1 protein] CTD PMID:19270784 bisphenol A increases expression ISO RGD:735516 6480464 bisphenol A results in increased expression of BCL2L1 protein CTD PMID:19270784 PMID:21277958 bisphenol A increases expression ISO RGD:735516 6480464 bisphenol A results in increased expression of BCL2L1 protein CTD PMID:21277958 PMID:19270784 brassinolide decreases expression ISO RGD:735516 6480464 brassinolide results in decreased expression of BCL2L1 protein CTD PMID:20833159 C60 fullerene decreases expression EXP   6480464 fullerene C60 results in decreased expression of BCL2L1 mRNA CTD PMID:19167457 cadmium dichloride decreases expression ISO RGD:1552009 6480464 Cadmium Chloride results in decreased expression of BCL2L1 mRNA CTD PMID:15501611 cadmium dichloride multiple interactions ISO RGD:1552009 6480464 pifithrin inhibits the reaction [Cadmium Chloride results in decreased expression of BCL2L1 protein]; more ... CTD PMID:19887573 calciol multiple interactions ISO RGD:735516 6480464 ABT-737 inhibits the reaction [Cholecalciferol promotes the reaction [BECN1 protein binds to BCL2L1 protein]]; more ... CTD PMID:18628207 calciol increases expression ISO RGD:735516 6480464 Cholecalciferol results in increased expression of BCL2L1 protein CTD PMID:18628207 calcitriol decreases expression ISO RGD:735516 6480464 Calcitriol results in decreased expression of BCL2L1 protein CTD PMID:12479363 PMID:10614618 calcitriol decreases expression ISO RGD:735516 6480464 Calcitriol results in decreased expression of BCL2L1 protein CTD PMID:10614618 PMID:12479363 calcitriol increases expression EXP   6480464 Calcitriol results in increased expression of BCL2L1 protein CTD PMID:17570329 camptothecin decreases response to substance EXP   6480464 BCL2L1 gene mutant form results in decreased susceptibility to Camptothecin CTD PMID:10970895 camptothecin multiple interactions EXP   6480464 Naphthoquinones analog promotes the reaction [Camptothecin results in increased expression of BCL2L1 protein] CTD PMID:19497415 camptothecin multiple interactions EXP   6480464 Mifepristone affects the reaction [Dexamethasone inhibits the reaction [Camptothecin results in decreased expression of BCL2L1 protein alternative form]] CTD PMID:19339209 camptothecin increases expression EXP   6480464 Camptothecin results in increased expression of BCL2L1 protein CTD PMID:19497415 camptothecin decreases expression EXP   6480464 Camptothecin results in decreased expression of BCL2L1 protein alternative form CTD PMID:19339209 capsaicin decreases expression ISO RGD:735516 6480464 Capsaicin results in decreased expression of BCL2L1 protein CTD PMID:17505005 capsaicin increases expression ISO RGD:735516 6480464 Capsaicin results in increased expression of BCL2L1 mRNA CTD PMID:19502594 carboplatin decreases expression ISO RGD:1552009 6480464 Carboplatin results in decreased expression of BCL2L1 protein CTD PMID:18483861 carboplatin multiple interactions EXP   6480464 Acetylcysteine inhibits the reaction [Carboplatin results in decreased expression of BCL2L1 protein] CTD PMID:18483861 carmustine affects response to substance ISO RGD:735516 6480464 BCL2L1 protein affects the susceptibility to Carmustine CTD PMID:15332326 carmustine decreases expression EXP   6480464 Carmustine results in decreased expression of BCL2L1 protein CTD PMID:19860839 carmustine multiple interactions ISO RGD:735516 6480464 [Fenretinide co-treated with Carmustine] results in decreased expression of BCL2L1 protein CTD PMID:16187019 carmustine decreases expression ISO RGD:735516 6480464 Carmustine results in decreased expression of BCL2L1 protein; more ... CTD PMID:15332326 carvedilol increases expression EXP   6480464 carvedilol results in increased expression of BCL2L1 protein CTD PMID:20079142 cefaloridine affects expression EXP   6480464 Cephaloridine affects the expression of BCL2L1 mRNA CTD PMID:18172885 celecoxib multiple interactions ISO RGD:735516 6480464 BCL2L1 mutant form promotes the reaction [celecoxib results in increased cleavage of CASP3 protein] CTD PMID:20104024 celecoxib increases expression ISO RGD:735516 6480464 celecoxib results in increased expression of BCL2L1 mRNA CTD PMID:17342322 celecoxib decreases expression ISO RGD:735516 6480464 celecoxib results in decreased expression of BCL2L1 protein CTD PMID:15688368 celecoxib multiple interactions ISO RGD:735516 6480464 [celecoxib co-treated with docetaxel] results in decreased expression of BCL2L1 protein; more ... CTD PMID:15688368 cetrorelix decreases expression ISO RGD:735516 6480464 cetrorelix results in decreased expression of BCL2L1 protein CTD PMID:21062912 chloroquine multiple interactions ISO RGD:1552009 6480464 BCL2L1 mutant form promotes the reaction [Chloroquine results in increased activity of CASP3 protein] CTD PMID:11589424 chlorpromazine increases expression ISO RGD:1552009 6480464 Chlorpromazine results in increased expression of BCL2L1 mRNA CTD PMID:21683644 chlorpyrifos multiple interactions ISO RGD:1552009 6480464 [Atrazine co-treated with Chlorpyrifos co-treated with Endosulfan] results in increased expression of BCL2L1 protein CTD PMID:22515965 chlorpyrifos increases expression ISO RGD:1552009 6480464 Chlorpyrifos results in increased expression of BCL2L1 protein CTD PMID:22515965 chrysazin increases expression ISO RGD:735516 6480464 danthron results in increased expression of BCL2L1 protein CTD PMID:21126053 chrysazin decreases expression ISO RGD:735516 6480464 danthron results in decreased expression of BCL2L1 protein CTD PMID:21126053 ciguatoxin CTX1B affects expression ISO RGD:1552009 6480464 Ciguatoxins affects the expression of BCL2L1 mRNA CTD PMID:18353800 cisplatin multiple interactions ISO RGD:735516 6480464 BCL2L1 protein results in decreased susceptibility to [Cisplatin co-treated with Etoposide] CTD PMID:15917659 cisplatin decreases expression ISO RGD:735516 6480464 Cisplatin results in decreased expression of BCL2L1 protein CTD PMID:17399942 more ... cisplatin decreases expression ISO RGD:735516 6480464 Cisplatin results in decreased expression of BCL2L1 protein CTD PMID:17399942 more ... cisplatin multiple interactions ISO RGD:1552009 6480464 IL6 gene mutant form promotes the reaction [Cisplatin results in increased expression of BCL2L1 protein]; more ... CTD PMID:19833167 cisplatin increases expression ISO RGD:1552009 6480464 Cisplatin results in increased expression of BCL2L1 mRNA; more ... CTD PMID:19833167 cisplatin decreases expression ISO RGD:735516 6480464 Cisplatin results in decreased expression of BCL2L1 protein CTD PMID:21052098 more ... cisplatin decreases expression ISO RGD:735516 6480464 Cisplatin results in decreased expression of BCL2L1 protein CTD PMID:21940343 more ... cisplatin decreases expression ISO RGD:735516 6480464 Cisplatin results in decreased expression of BCL2L1 protein CTD PMID:21737676 more ... cisplatin multiple interactions EXP   6480464 SB 203580 promotes the reaction [Cisplatin results in decreased expression of BCL2L1 protein] CTD PMID:19578154 cisplatin decreases expression EXP   6480464 Cisplatin results in decreased expression of BCL2L1 protein CTD PMID:19578154 cisplatin decreases expression ISO RGD:735516 6480464 Cisplatin results in decreased expression of BCL2L1 protein CTD PMID:21737676 more ... cisplatin decreases expression ISO RGD:735516 6480464 Cisplatin results in decreased expression of BCL2L1 mRNA CTD PMID:21737676 PMID:21940343 cisplatin decreases expression EXP   6480464 Cisplatin results in decreased expression of BCL2L1 mRNA CTD PMID:18172885 cisplatin decreases expression ISO RGD:1552009 6480464 Cisplatin results in decreased expression of BCL2L1 CTD PMID:21593185 cisplatin multiple interactions ISO RGD:1552009 6480464 SIRT1 mutant form inhibits the reaction [resveratrol inhibits the reaction [Cisplatin results in decreased expression of BCL2L1]]; more ... CTD PMID:21593185 cisplatin multiple interactions ISO RGD:735516 6480464 LGALS3 inhibits the reaction [Cisplatin results in increased degradation of BCL2L1 protein] CTD PMID:21821001 cisplatin multiple interactions ISO RGD:735516 6480464 [Quercetin results in increased susceptibility to Cisplatin] which results in decreased expression of BCL2L1 protein CTD PMID:16619537 cisplatin multiple interactions ISO RGD:735516 6480464 RELA protein mutant form inhibits the reaction [Cisplatin results in decreased expression of BCL2L1 protein]; more ... CTD PMID:21737676 cisplatin multiple interactions ISO RGD:735516 6480464 [TNFSF10 protein co-treated with Cisplatin] results in decreased expression of BCL2L1 protein CTD PMID:21252285 cisplatin multiple interactions ISO RGD:735516 6480464 ING4 protein promotes the reaction [Cisplatin results in decreased expression of BCL2L1 protein] CTD PMID:21052098 cisplatin multiple interactions ISO RGD:735516 6480464 [IL8 results in increased expression of BCL2L1 mRNA] which results in decreased susceptibility to Cisplatin; more ... CTD PMID:21742513 cisplatin multiple interactions ISO RGD:735516 6480464 Dexamethasone inhibits the reaction [Cisplatin results in decreased expression of BCL2L1 protein]; more ... CTD PMID:21940343 cisplatin increases expression ISO RGD:735516 6480464 Cisplatin results in increased expression of BCL2L1 protein CTD PMID:17619073 cisplatin increases degradation ISO RGD:735516 6480464 Cisplatin results in increased degradation of BCL2L1 protein CTD PMID:21821001 cisplatin decreases expression ISO RGD:735516 6480464 Cisplatin results in decreased expression of BCL2L1 protein CTD PMID:21737676 more ... cisplatin multiple interactions ISO RGD:735516 6480464 Cisplatin promotes the reaction [Metformin results in decreased expression of BCL2L1 protein] CTD PMID:21388661 cisplatin decreases expression ISO RGD:735516 6480464 Cisplatin results in decreased expression of BCL2L1 mRNA CTD PMID:21940343 PMID:21737676 cisplatin decreases response to substance ISO RGD:735516 6480464 BCL2L1 results in decreased susceptibility to Cisplatin CTD PMID:21849418 cisplatin decreases response to substance ISO RGD:735516 6480464 BCL2L1 protein results in decreased susceptibility to Cisplatin CTD PMID:16020667 citric acid multiple interactions ISO RGD:735516 6480464 [Citric Acid co-treated with zinc chloride] results in decreased expression of BCL2L1 protein CTD PMID:16624386 clofibrate multiple interactions ISO RGD:1552009 6480464 Clofibrate inhibits the reaction [[Fatty Acids, Nonesterified binds to ALB protein] which results in decreased expression of BCL2L1 protein] CTD PMID:21338618 clofibrate increases expression ISO RGD:1552009 6480464 Clofibrate results in increased expression of BCL2L1 protein CTD PMID:21338618 clonidine increases expression EXP   6480464 Clonidine results in increased expression of BCL2L1 mRNA CTD PMID:12423672 clonidine (amino form) increases expression EXP   6480464 Clonidine results in increased expression of BCL2L1 mRNA CTD PMID:12423672 clonidine (imino form) increases expression EXP   6480464 Clonidine results in increased expression of BCL2L1 mRNA CTD PMID:12423672 cobalt dichloride decreases expression EXP   6480464 cobaltous chloride results in decreased expression of BCL2L1 mRNA CTD PMID:18442013 cobalt dichloride multiple interactions EXP   6480464 scutellarin inhibits the reaction [cobaltous chloride results in decreased expression of BCL2L1 mRNA] CTD PMID:18442013 cocaine increases expression EXP   6480464 Cocaine results in increased expression of BCL2L1 mRNA; more ... CTD PMID:16076954 copper atom multiple interactions EXP   6480464 Acetylcysteine inhibits the reaction [[Copper co-treated with pyrrolidine dithiocarbamic acid] results in decreased expression of BCL2L1 protein] CTD PMID:22085843 copper(0) multiple interactions EXP   6480464 Acetylcysteine inhibits the reaction [[Copper co-treated with pyrrolidine dithiocarbamic acid] results in decreased expression of BCL2L1 protein] CTD PMID:22085843 cordycepin decreases expression ISO RGD:735516 6480464 cordycepin results in decreased expression of BCL2L1 protein CTD PMID:21310227 cordycepin multiple interactions ISO RGD:735516 6480464 Acetylcysteine inhibits the reaction [cordycepin results in decreased expression of BCL2L1 protein] CTD PMID:21310227 corticosterone increases expression EXP   6480464 Corticosterone results in increased expression of BCL2L1 protein; more ... CTD PMID:15755911 corticosterone multiple interactions EXP   6480464 [Corticosterone results in increased expression of BCL2L1 protein] which results in decreased susceptibility to Doxorubicin; more ... CTD PMID:15755911 crocidolite asbestos increases expression EXP   6480464 Asbestos, Crocidolite results in increased expression of BCL2L1 mRNA CTD PMID:12909582 crocidolite asbestos affects expression ISO RGD:735516 6480464 Asbestos, Crocidolite affects the expression of BCL2L1 mRNA CTD PMID:17331233 curcumin multiple interactions ISO RGD:735516 6480464 [Curcumin co-treated with Doxorubicin] affects the expression of BCL2L1 mRNA CTD PMID:15911101 curcumin decreases expression ISO RGD:735516 6480464 Curcumin results in decreased expression of BCL2L1 mRNA CTD PMID:15911101 more ... curcumin decreases expression ISO RGD:735516 6480464 Curcumin results in decreased expression of BCL2L1 protein CTD PMID:12497104 more ... curcumin decreases expression ISO RGD:735516 6480464 Curcumin results in decreased expression of BCL2L1 protein CTD PMID:19235267 more ... curcumin decreases expression ISO RGD:735516 6480464 Curcumin results in decreased expression of BCL2L1 mRNA CTD PMID:17596214 more ... curcumin decreases expression ISO RGD:735516 6480464 Curcumin results in decreased expression of BCL2L1 mRNA CTD PMID:17596214 more ... curcumin decreases expression ISO RGD:735516 6480464 Curcumin results in decreased expression of BCL2L1 protein CTD PMID:17148446 more ... curcumin decreases expression ISO RGD:735516 6480464 Curcumin results in decreased expression of BCL2L1 mRNA CTD PMID:19235267 more ... curcumin decreases expression ISO RGD:735516 6480464 Curcumin results in decreased expression of BCL2L1 protein CTD PMID:19235267 more ... curcumin decreases expression ISO RGD:735516 6480464 Curcumin analog results in decreased expression of BCL2L1 mRNA CTD PMID:17671737 PMID:19250217 curcumin decreases expression ISO RGD:735516 6480464 Curcumin results in decreased expression of BCL2L1 mRNA CTD PMID:19250217 more ... curcumin decreases expression ISO RGD:735516 6480464 Curcumin results in decreased expression of BCL2L1 protein CTD PMID:12497104 more ... curcumin decreases expression ISO RGD:735516 6480464 Curcumin results in decreased expression of BCL2L1 mRNA CTD PMID:19250217 more ... curcumin decreases expression ISO RGD:735516 6480464 Curcumin results in decreased expression of BCL2L1 protein CTD PMID:18226269 more ... curcumin decreases expression ISO RGD:1552009 6480464 Curcumin results in decreased expression of BCL2L1 protein CTD PMID:18829502 curcumin multiple interactions EXP   6480464 Curcumin inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of BCL2L1 protein] CTD PMID:15569404 curcumin multiple interactions ISO RGD:1552009 6480464 [Curcumin co-treated with gemcitabine] results in decreased expression of BCL2L1 protein CTD PMID:17440100 curcumin multiple interactions ISO RGD:735516 6480464 TNFSF10 protein promotes the reaction [Curcumin results in decreased expression of BCL2L1 protein] CTD PMID:18226269 curcumin decreases expression ISO RGD:735516 6480464 Curcumin results in decreased expression of BCL2L1 protein CTD PMID:17332930 more ... curcumin increases expression ISO RGD:735516 6480464 Curcumin results in increased expression of BCL2L1 mRNA CTD PMID:15911101 curcumin decreases expression ISO RGD:735516 6480464 Curcumin results in decreased expression of BCL2L1 mRNA CTD PMID:15911101 more ... curcumin multiple interactions ISO RGD:735516 6480464 Curcumin inhibits the reaction [TNF protein results in increased expression of BCL2L1 protein]; more ... CTD PMID:17640567 curcumin multiple interactions ISO RGD:735516 6480464 Curcumin inhibits the reaction [TNF protein results in increased expression of BCL2L1 mRNA] CTD PMID:16219905 curcumin multiple interactions ISO RGD:735516 6480464 [Curcumin co-treated with Isoflavones] results in decreased expression of BCL2L1 protein CTD PMID:18640131 curcumin multiple interactions ISO RGD:735516 6480464 Curcumin inhibits the reaction [Paclitaxel results in increased expression of BCL2L1 protein] CTD PMID:16243823 curcumin decreases expression ISO RGD:735516 6480464 Curcumin analog results in decreased expression of BCL2L1 mRNA CTD PMID:19250217 PMID:17671737 cycloheximide increases expression ISO RGD:735516 6480464 Cycloheximide results in increased expression of BCL2L1 protein alternative form CTD PMID:9326359 cycloheximide multiple interactions ISO RGD:735516 6480464 Dexamethasone inhibits the reaction [Cycloheximide results in increased expression of BCL2L1 protein] CTD PMID:9326359 cyclophosphamide increases expression EXP   6480464 Cyclophosphamide results in increased expression of BCL2L1 mRNA CTD PMID:11599041 cyclosporin A affects expression ISO RGD:735516 6480464 Cyclosporine affects the expression of BCL2L1 mRNA CTD PMID:20106945 cyclosporin A decreases expression ISO RGD:735516 6480464 Cyclosporine results in decreased expression of BCL2L1 mRNA CTD PMID:21632981 cypermethrin decreases expression EXP   6480464 cypermethrin results in decreased expression of BCL2L1 protein CTD PMID:22048644 cypermethrin multiple interactions EXP   6480464 HBEGF protein inhibits the reaction [cypermethrin results in decreased expression of BCL2L1 protein] CTD PMID:22048644 cytarabine multiple interactions ISO RGD:735516 6480464 BCL2L1 protein inhibits the reaction [Cytarabine results in increased degradation of PARP protein]; more ... CTD PMID:8840993 D-glucose multiple interactions EXP   6480464 BCL2L1 protein results in decreased susceptibility to [Oxygen deficiency co-treated with Glucose deficiency] CTD PMID:21124846 daidzein decreases expression ISO RGD:735516 6480464 daidzein results in decreased expression of BCL2L1 protein CTD PMID:12791511 dasatinib (anhydrous) decreases expression ISO RGD:735516 6480464 dasatinib results in decreased expression of BCL2L1 protein CTD PMID:18550857 dehydroepiandrosterone increases expression EXP   6480464 Dehydroepiandrosterone results in increased expression of BCL2L1 protein CTD PMID:16407456 dehydroepiandrosterone multiple interactions EXP   6480464 Dexamethasone inhibits the reaction [Dehydroepiandrosterone results in increased expression of BCL2L1 protein]; more ... CTD PMID:16407456 dehydroepiandrosterone sulfate increases expression EXP   6480464 Dehydroepiandrosterone Sulfate results in increased expression of BCL2L1 protein CTD PMID:16407456 dehydroepiandrosterone sulfate multiple interactions EXP   6480464 Pertussis Toxin inhibits the reaction [Dehydroepiandrosterone Sulfate results in increased expression of BCL2L1 protein] CTD PMID:16407456 dexamethasone multiple interactions ISO RGD:735516 6480464 Dexamethasone inhibits the reaction [Cisplatin results in decreased expression of BCL2L1 protein]; more ... CTD PMID:21940343 dexamethasone increases expression EXP   6480464 Dexamethasone results in increased expression of BCL2L1 protein alternative form CTD PMID:19339209 more ... dexamethasone decreases expression ISO RGD:735516 6480464 Dexamethasone results in decreased expression of BCL2L1 protein CTD PMID:15804364 PMID:19428934 dexamethasone increases expression EXP   6480464 Dexamethasone results in increased expression of BCL2L1 protein alternative form CTD PMID:15388240 more ... dexamethasone increases expression EXP   6480464 Dexamethasone results in increased expression of BCL2L1 protein alternative form CTD PMID:11319611 more ... dexamethasone increases expression EXP   6480464 Dexamethasone results in increased expression of BCL2L1 protein CTD PMID:17635642 PMID:10200566 dexamethasone increases expression ISO RGD:735516 6480464 Dexamethasone results in increased expression of BCL2L1 protein alternative form CTD PMID:11319611 PMID:17070682 dexamethasone multiple interactions EXP   6480464 Doxorubicin inhibits the reaction [Dexamethasone results in increased expression of BCL2L1 protein]; more ... CTD PMID:17635642 dexamethasone increases expression EXP   6480464 Dexamethasone results in increased expression of BCL2L1 protein alternative form CTD PMID:11319611 more ... dexamethasone increases expression EXP   6480464 Dexamethasone results in increased expression of BCL2L1 protein CTD PMID:10200566 PMID:17635642 dexamethasone multiple interactions EXP   6480464 Dexamethasone inhibits the reaction [Dehydroepiandrosterone results in increased expression of BCL2L1 protein] CTD PMID:16407456 dexamethasone increases expression EXP   6480464 Dexamethasone results in increased expression of BCL2L1 mRNA alternative form CTD PMID:11319611 dexamethasone multiple interactions ISO RGD:1552009 6480464 Dexamethasone inhibits the reaction [Puromycin Aminonucleoside results in decreased expression of BCL2L1 protein] CTD PMID:15987750 dexamethasone multiple interactions EXP   6480464 Dexamethasone inhibits the reaction [Camptothecin results in decreased expression of BCL2L1 protein alternative form]; more ... CTD PMID:19339209 dexamethasone increases stability ISO RGD:735516 6480464 Dexamethasone results in increased stability of BCL2L1 mRNA CTD PMID:9326359 dexamethasone increases expression ISO RGD:735516 6480464 Dexamethasone results in increased expression of BCL2L1 protein alternative form CTD PMID:17070682 PMID:11319611 dexamethasone increases expression ISO RGD:735516 6480464 Dexamethasone results in increased expression of BCL2L1 mRNA alternative form CTD PMID:17070682 dexamethasone decreases expression ISO RGD:735516 6480464 Dexamethasone results in decreased expression of BCL2L1 protein CTD PMID:15804364 dexamethasone multiple interactions ISO RGD:735516 6480464 Dexamethasone inhibits the reaction [Dactinomycin results in increased expression of BCL2L1 protein]; more ... CTD PMID:9326359 diarsenic trioxide decreases expression ISO RGD:735516 6480464 arsenic trioxide results in decreased expression of BCL2L1 protein CTD PMID:15665116 more ... diarsenic trioxide affects response to substance ISO RGD:735516 6480464 BCL2L1 protein affects the susceptibility to arsenic trioxide CTD PMID:10648417 PMID:11468182 diarsenic trioxide decreases expression ISO RGD:735516 6480464 arsenic trioxide results in decreased expression of BCL2L1 protein CTD PMID:11739184 more ... diarsenic trioxide multiple interactions ISO RGD:735516 6480464 [arsenic trioxide co-treated with Quercetin] results in decreased expression of BCL2L1 protein CTD PMID:18359480 diarsenic trioxide decreases expression ISO RGD:735516 6480464 arsenic trioxide results in decreased expression of BCL2L1 protein CTD PMID:11739184 more ... diarsenic trioxide multiple interactions ISO RGD:735516 6480464 [arsenic trioxide co-treated with epigallocatechin gallate] results in decreased expression of BCL2L1 protein CTD PMID:20950636 diarsenic trioxide decreases expression ISO RGD:735516 6480464 arsenic trioxide results in decreased expression of BCL2L1 protein CTD PMID:11739184 more ... diarsenic trioxide decreases expression ISO RGD:735516 6480464 arsenic trioxide results in decreased expression of BCL2L1 protein CTD PMID:16105982 more ... diarsenic trioxide decreases expression ISO RGD:735516 6480464 arsenic trioxide results in decreased expression of BCL2L1 protein CTD PMID:18546268 more ... diarsenic trioxide decreases expression ISO RGD:735516 6480464 arsenic trioxide results in decreased expression of BCL2L1 protein CTD PMID:11739184 more ... diarsenic trioxide decreases expression EXP   6480464 arsenic trioxide results in decreased expression of BCL2L1 mRNA CTD PMID:19730151 diarsenic trioxide multiple interactions ISO RGD:1552009 6480464 [Genistein co-treated with arsenic trioxide] results in decreased expression of BCL2L1 protein CTD PMID:21078540 diarsenic trioxide multiple interactions ISO RGD:735516 6480464 [Genistein co-treated with arsenic trioxide] results in decreased expression of BCL2L1 protein CTD PMID:21078540 diarsenic trioxide multiple interactions ISO RGD:735516 6480464 Genistein promotes the reaction [arsenic trioxide results in decreased expression of BCL2L1 protein] CTD PMID:18546268 diarsenic trioxide affects response to substance ISO RGD:735516 6480464 BCL2L1 protein affects the susceptibility to arsenic trioxide CTD PMID:11468182 diarsenic trioxide increases expression ISO RGD:735516 6480464 arsenic trioxide results in increased expression of BCL2L1 mRNA CTD PMID:17530438 diarsenic trioxide decreases expression ISO RGD:735516 6480464 arsenic trioxide results in decreased expression of BCL2L1 mRNA CTD PMID:19763917 diarsenic trioxide multiple interactions ISO RGD:735516 6480464 Acetylcysteine inhibits the reaction [[Sulindac co-treated with arsenic trioxide] results in increased phosphorylation of BCL2L1 protein]; more ... CTD PMID:18281123 diarsenic trioxide decreases expression ISO RGD:735516 6480464 arsenic trioxide results in decreased expression of BCL2L1 protein CTD PMID:15665116 more ... diazoxide multiple interactions ISO RGD:735516 6480464 5-hydroxydecanoic acid inhibits the reaction [Diazoxide results in increased expression of BCL2L1 mRNA alternative form]; more ... CTD PMID:15326191 diazoxide increases expression EXP   6480464 Isoproterenol results in increased expression of BCL2L1 protein CTD PMID:12738230 diazoxide multiple interactions EXP   6480464 CGP 20712A inhibits the reaction [Isoproterenol results in increased expression of BCL2L1 protein]; more ... CTD PMID:12738230 diazoxide increases expression EXP   6480464 Isoproterenol results in increased expression of BCL2L1 protein alternative form; more ... CTD PMID:16116328 diazoxide increases expression ISO RGD:1552009 6480464 Isoproterenol results in increased expression of BCL2L1 mRNA CTD PMID:20003209 diazoxide multiple interactions EXP   6480464 Perindopril inhibits the reaction [Isoproterenol results in increased expression of BCL2L1 mRNA alternative form] CTD PMID:16116328 diazoxide increases expression ISO RGD:735516 6480464 Diazoxide results in increased expression of BCL2L1 mRNA alternative form; more ... CTD PMID:15326191 dibenz[a,h]anthracene decreases expression ISO RGD:735516 6480464 1,2,5,6-dibenzanthracene results in decreased expression of BCL2L1 mRNA CTD PMID:16269432 dibenzo[a,l]pyrene decreases expression ISO RGD:735516 6480464 dibenzo(a,l)pyrene results in decreased expression of BCL2L1 mRNA CTD PMID:16269432 diclofenac increases expression ISO RGD:735516 6480464 Diclofenac results in increased expression of BCL2L1 mRNA alternative form CTD PMID:14609740 diethylstilbestrol decreases expression ISO RGD:1552009 6480464 Diethylstilbestrol results in decreased expression of BCL2L1 mRNA CTD PMID:15545218 dimethylarsinic acid increases expression ISO RGD:735516 6480464 Cacodylic Acid results in increased expression of BCL2L1 mRNA CTD PMID:17720352 dioxygen decreases expression EXP   6480464 Oxygen deficiency results in decreased expression of BCL2L1 mRNA; more ... CTD PMID:11042672 dioxygen multiple interactions EXP   6480464 BCL2L1 protein results in decreased susceptibility to [Oxygen deficiency co-treated with Glucose deficiency] CTD PMID:21124846 dioxygen multiple interactions ISO RGD:1552009 6480464 Oxygen inhibits the reaction [Oxygen deficiency results in increased expression of BCL2L1 mRNA] CTD PMID:22629407 dioxygen increases expression ISO RGD:1552009 6480464 Oxygen deficiency results in increased expression of BCL2L1 mRNA CTD PMID:22629407 dioxygen multiple interactions EXP   6480464 Phenylephrine inhibits the reaction [Oxygen deficiency results in decreased expression of BCL2L1 mRNA]; more ... CTD PMID:11042672 dipyridamole multiple interactions ISO RGD:735516 6480464 Dipyridamole inhibits the reaction [Adenosine results in decreased expression of BCL2L1 protein]; more ... CTD PMID:20063052 docetaxel anhydrous decreases response to substance ISO RGD:735516 6480464 BCL2L1 protein results in decreased susceptibility to docetaxel CTD PMID:16080463 docetaxel anhydrous decreases expression ISO RGD:735516 6480464 docetaxel results in decreased expression of BCL2L1 protein CTD PMID:15688368 PMID:17317842 docetaxel anhydrous decreases expression ISO RGD:735516 6480464 docetaxel results in decreased expression of BCL2L1 protein CTD PMID:17317842 PMID:15688368 docetaxel anhydrous multiple interactions ISO RGD:735516 6480464 [celecoxib co-treated with docetaxel] results in decreased expression of BCL2L1 protein CTD PMID:15688368 doxorubicin increases expression ISO RGD:735516 6480464 Doxorubicin results in increased expression of BCL2L1 mRNA CTD PMID:15939500 PMID:18560228 doxorubicin multiple interactions ISO RGD:735516 6480464 [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; more ... CTD PMID:19047049 doxorubicin multiple interactions ISO RGD:1552009 6480464 Silymarin inhibits the reaction [Doxorubicin results in decreased expression of BCL2L1 protein] CTD PMID:20144634 doxorubicin decreases expression ISO RGD:1552009 6480464 Doxorubicin results in decreased expression of BCL2L1 protein CTD PMID:17673183 PMID:20144634 doxorubicin decreases expression ISO RGD:735516 6480464 Doxorubicin results in decreased expression of BCL2L1 protein CTD PMID:16843435 more ... doxorubicin decreases expression ISO RGD:735516 6480464 Doxorubicin results in decreased expression of BCL2L1 protein CTD PMID:20884855 more ... doxorubicin decreases expression EXP   6480464 Doxorubicin results in decreased expression of BCL2L1 protein CTD PMID:14736733 PMID:18632596 doxorubicin increases expression ISO RGD:735516 6480464 Doxorubicin results in increased expression of BCL2L1 mRNA CTD PMID:18560228 PMID:15939500 doxorubicin increases expression ISO RGD:735516 6480464 Doxorubicin results in increased expression of BCL2L1 protein CTD PMID:17912235 PMID:19270784 doxorubicin increases expression ISO RGD:735516 6480464 Doxorubicin results in increased expression of BCL2L1 protein CTD PMID:19270784 PMID:17912235 doxorubicin multiple interactions ISO RGD:735516 6480464 bisphenol A promotes the reaction [Doxorubicin results in increased expression of BCL2L1 protein] CTD PMID:19270784 doxorubicin increases expression ISO RGD:1552009 6480464 Doxorubicin results in increased expression of BCL2L1 mRNA CTD PMID:15485691 PMID:15505089 doxorubicin decreases expression ISO RGD:735516 6480464 Doxorubicin results in decreased expression of BCL2L1 protein CTD PMID:16843435 more ... doxorubicin decreases response to substance ISO RGD:735516 6480464 BCL2L1 protein results in decreased susceptibility to Doxorubicin CTD PMID:11468182 PMID:15781649 doxorubicin decreases expression ISO RGD:735516 6480464 Doxorubicin results in decreased expression of BCL2L1 mRNA CTD PMID:19746155 doxorubicin multiple interactions ISO RGD:735516 6480464 Doxorubicin promotes the reaction [MAPK14 protein results in decreased expression of BCL2L1 protein] CTD PMID:16843435 doxorubicin multiple interactions ISO RGD:735516 6480464 [Curcumin co-treated with Doxorubicin] affects the expression of BCL2L1 mRNA CTD PMID:15911101 doxorubicin decreases expression ISO RGD:735516 6480464 Doxorubicin results in decreased expression of BCL2L1 protein CTD PMID:17922852 more ... doxorubicin decreases response to substance ISO RGD:735516 6480464 BCL2L1 protein results in decreased susceptibility to Doxorubicin CTD PMID:15781649 PMID:11468182 doxorubicin affects response to substance ISO RGD:735516 6480464 BCL2L1 protein affects the susceptibility to Doxorubicin CTD PMID:17923112 doxorubicin multiple interactions ISO RGD:735516 6480464 BCL2L1 protein inhibits the reaction [sildenafil results in increased activity of Doxorubicin]; more ... CTD PMID:20884855 doxorubicin multiple interactions ISO RGD:735516 6480464 BCL2L1 protein inhibits the reaction [BID protein results in increased susceptibility to Doxorubicin] CTD PMID:15289866 doxorubicin multiple interactions EXP   6480464 Ginkgo biloba extract 761 inhibits the reaction [Doxorubicin results in decreased expression of BCL2L1 protein] CTD PMID:18632596 doxorubicin decreases ubiquitination EXP   6480464 Doxorubicin results in decreased ubiquitination of BCL2L1 protein CTD PMID:12967636 doxorubicin decreases expression EXP   6480464 Doxorubicin results in decreased expression of BCL2L1 protein CTD PMID:18632596 doxorubicin multiple interactions EXP   6480464 GHRL protein inhibits the reaction [Doxorubicin results in decreased expression of BCL2L1 mRNA]; more ... CTD PMID:18400355 doxorubicin multiple interactions EXP   6480464 Doxorubicin inhibits the reaction [Dexamethasone results in increased expression of BCL2L1 protein] CTD PMID:17635642 doxorubicin decreases expression EXP   6480464 Doxorubicin results in decreased expression of BCL2L1 mRNA CTD PMID:18400355 doxorubicin decreases expression ISO RGD:1552009 6480464 Doxorubicin results in decreased expression of BCL2L1 protein CTD PMID:17673183 doxorubicin increases expression ISO RGD:1552009 6480464 Doxorubicin results in increased expression of BCL2L1 mRNA CTD PMID:15505089 PMID:15485691 doxorubicin multiple interactions EXP   6480464 [Corticosterone results in increased expression of BCL2L1 protein] which results in decreased susceptibility to Doxorubicin CTD PMID:15755911 doxorubicin multiple interactions ISO RGD:1552009 6480464 Doxycycline inhibits the reaction [Doxorubicin results in decreased expression of BCL2L1 protein] CTD PMID:17673183 doxorubicin affects expression ISO RGD:1552009 6480464 Doxorubicin affects the expression of BCL2L1 mRNA CTD PMID:16439991 doxorubicin decreases response to substance ISO RGD:1552009 6480464 BCL2L1 protein results in decreased susceptibility to Doxorubicin CTD PMID:16439991 doxorubicin multiple interactions ISO RGD:735516 6480464 NFKB1 protein affects the reaction [Doxorubicin results in increased expression of BCL2L1 protein] CTD PMID:17912235 doxorubicin multiple interactions ISO RGD:735516 6480464 pluronic block copolymer p85 inhibits the reaction [Doxorubicin results in increased expression of BCL2L1 mRNA] CTD PMID:15939500 doxorubicin increases expression ISO RGD:735516 6480464 Doxorubicin results in increased expression of BCL2L1 protein CTD PMID:17912235 doxycycline multiple interactions ISO RGD:1552009 6480464 Doxycycline inhibits the reaction [Doxorubicin results in decreased expression of BCL2L1 protein] CTD PMID:17673183 elemental selenium increases expression ISO RGD:735516 6480464 Selenium results in increased expression of BCL2L1 mRNA CTD PMID:19244175 elemental selenium multiple interactions EXP   6480464 [Selenium deficiency co-treated with Vitamin E deficiency] results in decreased expression of BCL2L1 mRNA CTD PMID:11444866 endosulfan increases expression ISO RGD:1552009 6480464 Endosulfan results in increased expression of BCL2L1 protein CTD PMID:22515965 endosulfan multiple interactions ISO RGD:1552009 6480464 [Atrazine co-treated with Chlorpyrifos co-treated with Endosulfan] results in increased expression of BCL2L1 protein CTD PMID:22515965 esculetin multiple interactions ISO RGD:735516 6480464 [esculetin co-treated with Paclitaxel] results in decreased expression of BCL2L1 protein CTD PMID:16051289 ethanol multiple interactions EXP   6480464 Ethanol promotes the reaction [BAX protein binds to BCL2L1 protein] CTD PMID:16035105 ethanol decreases expression EXP   6480464 Ethanol results in decreased expression of BCL2L1 mRNA CTD PMID:16098508 ethanol affects localization EXP   6480464 Ethanol affects the localization of BCL2L1 protein CTD PMID:16035105 etoposide multiple interactions ISO RGD:735516 6480464 BCL2L1 protein inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; more ... CTD PMID:8840993 etoposide multiple interactions ISO RGD:735516 6480464 [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; more ... CTD PMID:19047049 etoposide multiple interactions ISO RGD:735516 6480464 Etoposide inhibits the reaction [BAX protein binds to BCL2L1 protein]; more ... CTD PMID:10620629 etoposide affects expression ISO RGD:735516 6480464 Etoposide affects the expression of BCL2L1 protein CTD PMID:15215046 etoposide decreases response to substance ISO RGD:735516 6480464 BCL2L1 protein results in decreased susceptibility to Etoposide CTD PMID:11468182 etoposide multiple interactions ISO RGD:735516 6480464 BCL2L1 protein results in decreased susceptibility to [Cisplatin co-treated with Etoposide] CTD PMID:15917659 eugenol multiple interactions ISO RGD:1552009 6480464 Eugenol inhibits the reaction [Methylnitronitrosoguanidine results in increased expression of BCL2L1 mRNA] CTD PMID:20434464 fenofibrate decreases expression ISO RGD:735516 6480464 Fenofibrate results in decreased expression of BCL2L1 mRNA CTD PMID:20520642 fluoxetine increases expression EXP   6480464 Fluoxetine results in increased expression of BCL2L1 mRNA; more ... CTD PMID:21852994 fluoxetine decreases expression EXP   6480464 Fluoxetine results in decreased expression of BCL2L1 protein CTD PMID:19298536 fluoxetine affects expression EXP   6480464 Fluoxetine affects the expression of BCL2L1 mRNA CTD PMID:21740920 flutamide decreases expression ISO RGD:1552009 6480464 Flutamide results in decreased expression of BCL2L1 mRNA CTD PMID:19442681 folic acid decreases expression ISO RGD:1552009 6480464 Folic Acid results in decreased expression of BCL2L1 protein CTD PMID:16595132 folic acid multiple interactions ISO RGD:1552009 6480464 TNF protein affects the reaction [Folic Acid results in decreased expression of BCL2L1 protein] CTD PMID:16595132 fucoxanthin multiple interactions ISO RGD:735516 6480464 Acetylcysteine inhibits the reaction [fucoxanthin results in decreased expression of BCL2L1 protein] CTD PMID:20594983 fucoxanthin decreases expression ISO RGD:735516 6480464 fucoxanthin results in decreased expression of BCL2L1 protein CTD PMID:20594983 furan increases methylation EXP   6480464 furan results in increased methylation of BCL2L1 gene CTD PMID:22079235 gamma-hexachlorocyclohexane increases expression EXP   6480464 Lindane results in increased expression of BCL2L1 protein CTD PMID:19041923 gamma-hexachlorocyclohexane increases expression EXP   6480464 Lindane results in increased expression of BCL2L1 protein CTD PMID:19041923 PMID:22001173 gamma-hexachlorocyclohexane multiple interactions EXP   6480464 Ro 31-8220 inhibits the reaction [Lindane results in increased expression of BCL2L1 protein]; more ... CTD PMID:22001173 geldanamycin decreases response to substance ISO RGD:735516 6480464 BCL2L1 protein results in decreased susceptibility to geldanamycin CTD PMID:15781649 geldanamycin multiple interactions ISO RGD:735516 6480464 [geldanamycin co-treated with bortezomib] results in decreased expression of BCL2L1 protein CTD PMID:15781649 genistein multiple interactions ISO RGD:735516 6480464 [Genistein co-treated with arsenic trioxide] results in decreased expression of BCL2L1 protein CTD PMID:21078540 genistein decreases expression ISO RGD:1552009 6480464 Genistein results in decreased expression of BCL2L1 mRNA CTD PMID:21048042 genistein decreases expression ISO RGD:735516 6480464 Genistein results in decreased expression of BCL2L1 protein CTD PMID:12791511 more ... genistein decreases expression ISO RGD:735516 6480464 Genistein results in decreased expression of BCL2L1 protein CTD PMID:21078540 more ... genistein decreases expression ISO RGD:735516 6480464 Genistein results in decreased expression of BCL2L1 protein CTD PMID:18546268 more ... genistein decreases expression ISO RGD:735516 6480464 Genistein results in decreased expression of BCL2L1 protein CTD PMID:21078540 more ... genistein decreases expression ISO RGD:1552009 6480464 Genistein results in decreased expression of BCL2L1 protein CTD PMID:21078540 genistein multiple interactions ISO RGD:1552009 6480464 [Genistein co-treated with arsenic trioxide] results in decreased expression of BCL2L1 protein CTD PMID:21078540 genistein decreases expression ISO RGD:735516 6480464 Genistein results in decreased expression of BCL2L1 protein CTD PMID:18546268 more ... genistein multiple interactions ISO RGD:735516 6480464 Genistein promotes the reaction [arsenic trioxide results in decreased expression of BCL2L1 protein] CTD PMID:18546268 glucose multiple interactions EXP   6480464 BCL2L1 protein results in decreased susceptibility to [Oxygen deficiency co-treated with Glucose deficiency] CTD PMID:21124846 glutathione multiple interactions ISO RGD:735516 6480464 Glutathione inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of BCL2L1 protein]] CTD PMID:17640567 haloperidol multiple interactions EXP   6480464 EPO protein inhibits the reaction [Haloperidol results in decreased expression of BCL2L1 protein] CTD PMID:17805306 haloperidol increases expression EXP   6480464 Haloperidol results in increased expression of BCL2L1 protein CTD PMID:16462815 haloperidol decreases expression EXP   6480464 Haloperidol results in decreased expression of BCL2L1 protein CTD PMID:17805306 hyaluronic acid multiple interactions ISO RGD:735516 6480464 [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 mRNA; more ... CTD PMID:19047049 hydrogen peroxide increases expression EXP   6480464 Hydrogen Peroxide results in increased expression of BCL2L1 mRNA CTD PMID:14689451 hydrogen peroxide affects expression ISO RGD:735516 6480464 Hydrogen Peroxide affects the expression of BCL2L1 protein CTD PMID:21179406 hydrogen peroxide decreases expression ISO RGD:735516 6480464 Hydrogen Peroxide results in decreased expression of BCL2L1 protein CTD PMID:22269385 hydrogen peroxide decreases response to substance EXP   6480464 BCL2L1 gene mutant form results in decreased susceptibility to Hydrogen Peroxide CTD PMID:10970895 hydroxyurea decreases response to substance EXP   6480464 BCL2L1 gene mutant form results in decreased susceptibility to Hydroxyurea CTD PMID:10970895 ibuprofen multiple interactions ISO RGD:735516 6480464 calyculin A inhibits the reaction [[Ibuprofen co-treated with epigallocatechin gallate] results in decreased expression of BCL2L1 mRNA alternative form]; more ... CTD PMID:18348186 imatinib decreases expression ISO RGD:735516 6480464 imatinib results in decreased expression of BCL2L1 protein CTD PMID:16960866 PMID:11179439 imatinib decreases expression ISO RGD:735516 6480464 imatinib results in decreased expression of BCL2L1 protein CTD PMID:11179439 PMID:16960866 imatinib multiple interactions ISO RGD:735516 6480464 [vorinostat co-treated with imatinib] results in decreased expression of BCL2L1 protein CTD PMID:12446442 indole-3-methanol decreases expression ISO RGD:735516 6480464 indole-3-carbinol results in decreased expression of BCL2L1 CTD PMID:16082211 indomethacin decreases expression ISO RGD:735516 6480464 Indomethacin results in decreased expression of BCL2L1 protein CTD PMID:16572323 PMID:11062132 indomethacin decreases expression ISO RGD:735516 6480464 Indomethacin results in decreased expression of BCL2L1 protein CTD PMID:11062132 PMID:16572323 indomethacin multiple interactions EXP   6480464 lansoprazole inhibits the reaction [Indomethacin results in decreased expression of BCL2L1 protein] CTD PMID:18375387 indomethacin multiple interactions EXP   6480464 Melatonin inhibits the reaction [Indomethacin results in decreased expression of BCL2L1 mRNA] CTD PMID:19220725 indomethacin decreases expression EXP   6480464 Indomethacin results in decreased expression of BCL2L1 protein CTD PMID:18375387 indomethacin decreases expression EXP   6480464 Indomethacin results in decreased expression of BCL2L1 mRNA CTD PMID:19220725 iron atom multiple interactions ISO RGD:735516 6480464 [Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2L1 protein; more ... CTD PMID:19620254 isoliquiritigenin decreases expression ISO RGD:735516 6480464 isoliquiritigenin results in decreased expression of BCL2L1 protein CTD PMID:15729620 isoprenaline increases expression ISO RGD:1552009 6480464 Isoproterenol results in increased expression of BCL2L1 mRNA CTD PMID:20003209 isoprenaline multiple interactions EXP   6480464 Perindopril inhibits the reaction [Isoproterenol results in increased expression of BCL2L1 mRNA alternative form] CTD PMID:16116328 isoprenaline increases expression EXP   6480464 Isoproterenol results in increased expression of BCL2L1 protein CTD PMID:12738230 isoprenaline increases expression EXP   6480464 Isoproterenol results in increased expression of BCL2L1 mRNA alternative form; more ... CTD PMID:16116328 isoprenaline multiple interactions EXP   6480464 CGP 20712A inhibits the reaction [Isoproterenol results in increased expression of BCL2L1 protein]; more ... CTD PMID:12738230 isotretinoin increases expression ISO RGD:735516 6480464 Isotretinoin results in increased expression of BCL2L1 mRNA; more ... CTD PMID:21159604 isotretinoin decreases expression ISO RGD:735516 6480464 Isotretinoin results in decreased expression of BCL2L1 protein CTD PMID:16135400 kaempferol multiple interactions ISO RGD:735516 6480464 TP53 protein affects the reaction [kaempferol promotes the reaction [BBC3 protein binds to BCL2L1 protein]] CTD PMID:19028473 L-ascorbic acid multiple interactions EXP   6480464 Ascorbic Acid inhibits the reaction [Streptozocin results in decreased expression of BCL2L1 protein] CTD PMID:18758938 L-ascorbic acid multiple interactions EXP   6480464 Ascorbic Acid inhibits the reaction [Potassium Dichromate results in decreased expression of BCL2L1 protein] CTD PMID:21262251 lactacystin multiple interactions ISO RGD:1552009 6480464 lactacystin inhibits the reaction [Acetaminophen results in decreased expression of BCL2L1 protein] CTD PMID:15673306 lansoprazole multiple interactions EXP   6480464 lansoprazole inhibits the reaction [Indomethacin results in decreased expression of BCL2L1 protein] CTD PMID:18375387 leptomycin B multiple interactions ISO RGD:735516 6480464 leptomycin B inhibits the reaction [Tretinoin results in decreased expression of BCL2L1 protein] CTD PMID:14592536 lithium chloride increases expression ISO RGD:735516 6480464 Lithium Chloride results in increased expression of BCL2L1 mRNA CTD PMID:19101580 lithium chloride increases expression ISO RGD:735516 6480464 Lithium Chloride results in increased expression of BCL2L1 protein CTD PMID:22493441 lithium chloride increases expression ISO RGD:735516 6480464 Lithium Chloride results in increased expression of BCL2L1 mRNA CTD PMID:19101580 PMID:22493441 lithocholic acid increases expression ISO RGD:1552009 6480464 Lithocholic Acid results in increased expression of BCL2L1 mRNA CTD PMID:19433268 lithocholic acid multiple interactions ISO RGD:1552009 6480464 1,4-bis(2-(3,5-dichloropyridyloxy))benzene inhibits the reaction [Lithocholic Acid results in increased expression of BCL2L1 mRNA]; more ... CTD PMID:19433268 lonidamine decreases expression ISO RGD:735516 6480464 lonidamine results in decreased expression of BCL2L1 protein CTD PMID:21889928 lovastatin decreases expression EXP   6480464 Lovastatin results in decreased expression of BCL2L1 protein CTD PMID:11178870 lovastatin multiple interactions EXP   6480464 Mevalonic Acid inhibits the reaction [Lovastatin results in decreased expression of BCL2L1 protein] CTD PMID:11178870 lutein increases expression ISO RGD:735516 6480464 Lutein results in increased expression of BCL2L1 protein CTD PMID:10750663 luteolin decreases expression ISO RGD:735516 6480464 Luteolin results in decreased expression of BCL2L1 protein CTD PMID:21601631 LY294002 multiple interactions ISO RGD:735516 6480464 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Lipopolysaccharides results in increased expression of BCL2L1 protein] CTD PMID:18789402 LY294002 multiple interactions ISO RGD:735516 6480464 [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Tamoxifen] results in decreased expression of BCL2L1 mRNA; more ... CTD PMID:22046442 LY294002 decreases expression ISO RGD:735516 6480464 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of BCL2L1 protein CTD PMID:14762343 PMID:21173233 LY294002 increases degradation ISO RGD:735516 6480464 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased degradation of BCL2L1 protein CTD PMID:21821001 LY294002 multiple interactions ISO RGD:735516 6480464 LGALS3 inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased degradation of BCL2L1 protein] CTD PMID:21821001 LY294002 multiple interactions ISO RGD:1552009 6480464 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Lipopolysaccharides results in increased expression of BCL2L1 protein] CTD PMID:18789402 LY294002 decreases expression ISO RGD:735516 6480464 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of BCL2L1 protein CTD PMID:14762343 maneb multiple interactions ISO RGD:735516 6480464 [Paraquat co-treated with Maneb] results in decreased expression of BCL2L1 protein CTD PMID:15824117 mangiferin decreases expression ISO RGD:735516 6480464 mangiferin results in decreased expression of BCL2L1 protein CTD PMID:21547680 melamine decreases expression ISO RGD:735516 6480464 melamine results in decreased expression of BCL2L1 protein CTD PMID:22915474 melatonin multiple interactions EXP   6480464 Melatonin inhibits the reaction [Indomethacin results in decreased expression of BCL2L1 mRNA] CTD PMID:19220725 melatonin multiple interactions ISO RGD:735516 6480464 Melatonin promotes the reaction [Puromycin results in decreased expression of BCL2L1 protein] CTD PMID:21244482 mercaptopurine decreases expression ISO RGD:735516 6480464 6-Mercaptopurine results in decreased expression of BCL2L1 protein CTD PMID:12697733 metformin multiple interactions ISO RGD:735516 6480464 Cisplatin promotes the reaction [Metformin results in decreased expression of BCL2L1 protein] CTD PMID:21388661 metformin decreases expression ISO RGD:735516 6480464 Metformin results in decreased expression of BCL2L1 protein CTD PMID:21388661 methamphetamine affects expression EXP   6480464 Methamphetamine affects the expression of BCL2L1 mRNA alternative form CTD PMID:10336889 methoxychlor increases expression ISO RGD:1552009 6480464 Methoxychlor results in increased expression of BCL2L1 mRNA CTD PMID:20829426 methoxychlor increases expression ISO RGD:1552009 6480464 Methoxychlor results in increased expression of BCL2L1 mRNA CTD PMID:20829426 PMID:23000595 methylmercury(1+) multiple interactions EXP   6480464 [Benzene co-treated with methylmercury II co-treated with Trichloroethylene] results in increased expression of BCL2L1 mRNA CTD PMID:17905399 metoprolol multiple interactions EXP   6480464 Metoprolol inhibits the reaction [Isoproterenol results in increased expression of BCL2L1 protein] CTD PMID:12738230 mevalonic acid multiple interactions EXP   6480464 Mevalonic Acid inhibits the reaction [Lovastatin results in decreased expression of BCL2L1 protein] CTD PMID:11178870 mifepristone multiple interactions EXP   6480464 Mifepristone affects the reaction [Dexamethasone inhibits the reaction [Camptothecin results in decreased expression of BCL2L1 protein alternative form]] CTD PMID:19339209 mifepristone multiple interactions EXP   6480464 Mifepristone inhibits the reaction [Corticosterone results in increased expression of BCL2L1 protein] CTD PMID:15755911 mifepristone multiple interactions EXP   6480464 Mifepristone inhibits the reaction [Dexamethasone results in increased expression of BCL2L1 protein] CTD PMID:17635642 mitomycin C decreases expression ISO RGD:735516 6480464 Mitomycin results in decreased expression of BCL2L1 mRNA CTD PMID:18615204 mitomycin C increases expression ISO RGD:735516 6480464 Mitomycin results in increased expression of BCL2L1 protein CTD PMID:11867586 mitoxantrone multiple interactions ISO RGD:735516 6480464 BCL2L1 protein inhibits the reaction [Mitoxantrone results in increased degradation of PARP protein]; more ... CTD PMID:8840993 mono(2-ethylhexyl) phthalate multiple interactions ISO RGD:1552009 6480464 AKT1 protein affects the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of BCL2L1 mRNA]; more ... CTD PMID:18755736 mono(2-ethylhexyl) phthalate increases expression ISO RGD:1552009 6480464 mono-(2-ethylhexyl)phthalate results in increased expression of BCL2L1 protein; more ... CTD PMID:18755736 monocrotaline multiple interactions ISO RGD:1552009 6480464 [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of BCL2L1 mRNA CTD PMID:21224054 morphine decreases expression EXP   6480464 Morphine results in decreased expression of BCL2L1 mRNA CTD PMID:15183518 N,N-dimethylformamide multiple interactions EXP   6480464 [Dimethylformamide co-treated with Carbon Tetrachloride] results in decreased expression of BCL2L1 protein CTD PMID:20097184 N-acetyl-L-cysteine multiple interactions ISO RGD:735516 6480464 Acetylcysteine inhibits the reaction [nickel acetate results in decreased expression of BCL2L1 protein]; more ... CTD PMID:22245127 N-acetyl-L-cysteine multiple interactions EXP   6480464 Acetylcysteine inhibits the reaction [[Copper co-treated with pyrrolidine dithiocarbamic acid] results in decreased expression of BCL2L1 protein] CTD PMID:22085843 N-acetyl-L-cysteine multiple interactions ISO RGD:735516 6480464 Acetylcysteine inhibits the reaction [cordycepin results in decreased expression of BCL2L1 protein] CTD PMID:21310227 N-acetyl-L-cysteine multiple interactions ISO RGD:735516 6480464 Acetylcysteine inhibits the reaction [fucoxanthin results in decreased expression of BCL2L1 protein] CTD PMID:20594983 N-acetyl-L-cysteine multiple interactions EXP   6480464 Acetylcysteine inhibits the reaction [Carboplatin results in decreased expression of BCL2L1 protein] CTD PMID:18483861 N-acetyl-L-cysteine multiple interactions ISO RGD:735516 6480464 Acetylcysteine inhibits the reaction [[Sulindac co-treated with arsenic trioxide] results in increased phosphorylation of BCL2L1 protein] CTD PMID:18281123 N-methyl-N'-nitro-N-nitrosoguanidine multiple interactions ISO RGD:735516 6480464 BCL2L1 protein results in decreased susceptibility to [Methylnitronitrosoguanidine co-treated with 2-((R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide] CTD PMID:18376143 N-methyl-N'-nitro-N-nitrosoguanidine increases expression ISO RGD:1552009 6480464 Methylnitronitrosoguanidine results in increased expression of BCL2L1 mRNA CTD PMID:20434464 N-methyl-N'-nitro-N-nitrosoguanidine multiple interactions ISO RGD:1552009 6480464 Eugenol inhibits the reaction [Methylnitronitrosoguanidine results in increased expression of BCL2L1 mRNA] CTD PMID:20434464 N-nitrosodiethylamine multiple interactions EXP   6480464 chrysin inhibits the reaction [Diethylnitrosamine results in increased expression of BCL2L1 protein]; more ... CTD PMID:21167192 N-nitrosodiethylamine increases expression ISO RGD:1552009 6480464 Diethylnitrosamine results in increased expression of BCL2L1 mRNA CTD PMID:21607683 N-nitrosodiethylamine increases expression EXP   6480464 Diethylnitrosamine results in increased expression of BCL2L1 protein CTD PMID:21554863 PMID:21167192 N-nitrosodiethylamine increases expression EXP   6480464 Diethylnitrosamine results in increased expression of BCL2L1 protein CTD PMID:21167192 PMID:21554863 N-nitrosodiethylamine multiple interactions EXP   6480464 5,7-dimethoxyflavone inhibits the reaction [Diethylnitrosamine results in increased expression of BCL2L1 protein] CTD PMID:21554863 N-nitrosodiethylamine increases expression EXP   6480464 Diethylnitrosamine results in increased expression of BCL2L1 mRNA; more ... CTD PMID:21167192 N-nitrosodiethylamine multiple interactions EXP   6480464 [Diethylnitrosamine co-treated with Phenobarbital] results in decreased expression of BCL2L1 protein; more ... CTD PMID:11749691 N-nitrosodiethylamine multiple interactions EXP   6480464 [Diethylnitrosamine co-treated with 2-Acetylaminofluorene] affects the expression of BCL2L1 protein; more ... CTD PMID:11915028 N-nitrosodimethylamine multiple interactions EXP   6480464 Estradiol inhibits the reaction [Dimethylnitrosamine results in decreased expression of BCL2L1 protein]; more ... CTD PMID:14659978 N-nitrosodimethylamine decreases expression EXP   6480464 Dimethylnitrosamine results in decreased expression of BCL2L1 protein CTD PMID:14659978 NAD zwitterion multiple interactions ISO RGD:1552009 6480464 NAD inhibits the reaction [Acetaminophen results in decreased expression of BCL2L1 protein] CTD PMID:11461765 NAD(+) multiple interactions ISO RGD:1552009 6480464 NAD inhibits the reaction [Acetaminophen results in decreased expression of BCL2L1 protein] CTD PMID:11461765 nickel dichloride increases expression ISO RGD:735516 6480464 nickel chloride results in increased expression of BCL2L1 protein CTD PMID:21837363 nickel dichloride decreases expression EXP   6480464 nickel chloride results in decreased expression of BCL2L1 protein CTD PMID:20391133 nickel sulfate increases expression ISO RGD:735516 6480464 nickel sulfate results in increased expression of BCL2L1 protein CTD PMID:21776270 nitric oxide decreases expression ISO RGD:735516 6480464 Nitric Oxide results in decreased expression of BCL2L1 protein CTD PMID:15126337 nitroprusside multiple interactions EXP   6480464 MAPK3 protein affects the susceptibility to [Nitroprusside results in decreased expression of BCL2L1 mRNA]; more ... CTD PMID:20132804 nitroprusside decreases expression EXP   6480464 Nitroprusside results in decreased expression of BCL2L1 protein; more ... CTD PMID:20132804 ochratoxin A decreases expression ISO RGD:735516 6480464 ochratoxin A results in decreased expression of BCL2L1 protein CTD PMID:15056805 ochratoxin A increases expression EXP   6480464 ochratoxin A results in increased expression of BCL2L1 mRNA CTD PMID:23208426 ochratoxin A decreases response to substance ISO RGD:735516 6480464 BCL2L1 protein results in decreased susceptibility to ochratoxin A CTD PMID:20549612 oxaliplatin decreases expression ISO RGD:735516 6480464 oxaliplatin results in decreased expression of BCL2L1 protein CTD PMID:16024531 paclitaxel decreases response to substance ISO RGD:735516 6480464 BCL2L1 protein results in decreased susceptibility to Paclitaxel CTD PMID:16080463 more ... paclitaxel decreases response to substance ISO RGD:735516 6480464 BCL2L1 protein results in decreased susceptibility to Paclitaxel CTD PMID:16080463 more ... paclitaxel decreases response to substance ISO RGD:735516 6480464 BCL2L1 protein results in decreased susceptibility to Paclitaxel CTD PMID:16275990 more ... paclitaxel decreases expression ISO RGD:735516 6480464 Paclitaxel results in decreased expression of BCL2L1 protein CTD PMID:11774260 PMID:14749477 paclitaxel decreases response to substance ISO RGD:735516 6480464 BCL2L1 protein results in decreased susceptibility to Paclitaxel CTD PMID:11468182 more ... paclitaxel increases phosphorylation ISO RGD:735516 6480464 Paclitaxel results in increased phosphorylation of BCL2L1 protein CTD PMID:18521433 paclitaxel increases expression ISO RGD:735516 6480464 Paclitaxel results in increased expression of BCL2L1 mRNA; more ... CTD PMID:10822281 paclitaxel decreases expression ISO RGD:735516 6480464 Paclitaxel results in decreased expression of BCL2L1 protein CTD PMID:14749477 PMID:11774260 paclitaxel decreases expression ISO RGD:735516 6480464 Paclitaxel results in decreased expression of BCL2L1 mRNA CTD PMID:18058816 paclitaxel multiple interactions ISO RGD:735516 6480464 [IL8 results in increased expression of BCL2L1 mRNA] which results in decreased susceptibility to Paclitaxel; more ... CTD PMID:21742513 paclitaxel multiple interactions ISO RGD:735516 6480464 [esculetin co-treated with Paclitaxel] results in decreased expression of BCL2L1 protein CTD PMID:16051289 paclitaxel multiple interactions ISO RGD:735516 6480464 Curcumin inhibits the reaction [Paclitaxel results in increased expression of BCL2L1 protein] CTD PMID:16243823 paracetamol decreases expression ISO RGD:1552009 6480464 Acetaminophen results in decreased expression of BCL2L1 protein CTD PMID:18467506 more ... paracetamol decreases expression ISO RGD:1552009 6480464 Acetaminophen results in decreased expression of BCL2L1 protein CTD PMID:11461765 more ... paracetamol decreases expression ISO RGD:735516 6480464 Acetaminophen results in decreased expression of BCL2L1 mRNA CTD PMID:21420995 paracetamol decreases expression ISO RGD:1552009 6480464 Acetaminophen results in decreased expression of BCL2L1 protein CTD PMID:11461765 more ... paracetamol multiple interactions EXP   6480464 anthra(1,9-cd)pyrazol-6(2H)-one inhibits the reaction [Acetaminophen results in increased expression of BCL2L1 protein modified form]; more ... CTD PMID:20166895 paracetamol increases expression EXP   6480464 Acetaminophen results in increased expression of BCL2L1 protein modified form CTD PMID:20166895 paracetamol increases expression EXP   6480464 Acetaminophen results in increased expression of BCL2L1 mRNA CTD PMID:19784758 paracetamol decreases expression EXP   6480464 Acetaminophen results in decreased expression of BCL2L1 mRNA CTD PMID:19784758 paracetamol affects expression EXP   6480464 Acetaminophen affects the expression of BCL2L1 mRNA CTD PMID:19784758 paracetamol multiple interactions ISO RGD:1552009 6480464 KITL protein inhibits the reaction [Acetaminophen results in decreased expression of BCL2L1 protein] CTD PMID:18467506 paracetamol multiple interactions ISO RGD:1552009 6480464 lactacystin inhibits the reaction [Acetaminophen results in decreased expression of BCL2L1 protein] CTD PMID:15673306 paracetamol increases expression ISO RGD:1552009 6480464 Acetaminophen results in increased expression of BCL2L1 mRNA CTD PMID:11264010 paracetamol decreases expression ISO RGD:1552009 6480464 Acetaminophen results in decreased expression of BCL2L1 protein CTD PMID:15673306 more ... paracetamol affects expression ISO RGD:1552009 6480464 Acetaminophen affects the expression of BCL2L1 mRNA CTD PMID:17562736 paracetamol multiple interactions ISO RGD:1552009 6480464 Acetaminophen affects the expression of and affects the phosphorylation of BCL2L1 protein CTD PMID:10663392 paracetamol multiple interactions ISO RGD:1552009 6480464 4-aminobenzamide inhibits the reaction [Acetaminophen results in decreased expression of BCL2L1 protein]; more ... CTD PMID:11461765 paracetamol affects expression ISO RGD:735516 6480464 Acetaminophen affects the expression of BCL2L1 mRNA CTD PMID:11896290 paracetamol decreases expression ISO RGD:1552009 6480464 Acetaminophen results in decreased expression of BCL2L1 protein CTD PMID:18467506 more ... paraquat multiple interactions ISO RGD:735516 6480464 [Paraquat co-treated with Maneb] results in decreased expression of BCL2L1 protein CTD PMID:15824117 paraquat affects expression EXP   6480464 Paraquat affects the expression of BCL2L1 mRNA CTD PMID:16854511 paraquat decreases response to substance EXP   6480464 BCL2L1 gene mutant form results in decreased susceptibility to Paraquat CTD PMID:10970895 paraquat increases expression ISO RGD:1552009 6480464 Paraquat results in increased expression of BCL2L1 protein CTD PMID:16797015 paraquat increases expression ISO RGD:1552009 6480464 Paraquat results in increased expression of BCL2L1 mRNA CTD PMID:12595580 paraquat multiple interactions ISO RGD:1552009 6480464 GPX1 protein affects the reaction [Paraquat results in increased expression of BCL2L1 protein] CTD PMID:12654481 parathion decreases expression EXP   6480464 Parathion results in decreased expression of BCL2L1 mRNA CTD PMID:19784758 perindopril multiple interactions EXP   6480464 Perindopril inhibits the reaction [Isoproterenol results in increased expression of BCL2L1 mRNA alternative form] CTD PMID:16116328 phenethyl isothiocyanate decreases expression ISO RGD:735516 6480464 phenethyl isothiocyanate results in decreased expression of BCL2L1 protein CTD PMID:16054126 phenobarbital multiple interactions EXP   6480464 [Diethylnitrosamine co-treated with Phenobarbital] results in decreased expression of BCL2L1 protein CTD PMID:11749691 phenobarbital multiple interactions ISO RGD:1552009 6480464 Phenobarbital inhibits the reaction [Lithocholic Acid results in increased expression of BCL2L1 mRNA] CTD PMID:19433268 phenylephrine multiple interactions EXP   6480464 Phenylephrine inhibits the reaction [Oxygen deficiency results in decreased expression of BCL2L1 mRNA]; more ... CTD PMID:11042672 phenytoin multiple interactions ISO RGD:1552009 6480464 [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of BCL2L1 mRNA CTD PMID:21224054 phorbol 13-acetate 12-myristate increases expression ISO RGD:735516 6480464 Tetradecanoylphorbol Acetate results in increased expression of BCL2L1 protein CTD PMID:11139146 phorbol 13-acetate 12-myristate multiple interactions ISO RGD:735516 6480464 [indirubin-3'-monoxime co-treated with Tetradecanoylphorbol Acetate] results in increased expression of BCL2L1 mRNA CTD PMID:18958680 pirinixic acid increases expression ISO RGD:1552009 6480464 pirinixic acid results in increased expression of BCL2L1 mRNA CTD PMID:18445702 pirinixic acid multiple interactions ISO RGD:1552009 6480464 [pirinixic acid results in increased expression of BCL2L1 protein] inhibits the reaction [Iron-Dextran Complex results in increased activity of CASP3 protein] CTD PMID:20709802 pirinixic acid increases expression ISO RGD:1552009 6480464 pirinixic acid results in increased expression of BCL2L1 protein CTD PMID:20709802 potassium dichromate affects localization EXP   6480464 Potassium Dichromate affects the localization of BCL2L1 protein CTD PMID:21262251 potassium dichromate decreases expression EXP   6480464 Potassium Dichromate results in decreased expression of BCL2L1 protein CTD PMID:21262251 potassium dichromate multiple interactions EXP   6480464 Ascorbic Acid inhibits the reaction [Potassium Dichromate results in decreased expression of BCL2L1 protein] CTD PMID:21262251 pregnenolone 16alpha-carbonitrile multiple interactions ISO RGD:1552009 6480464 Pregnenolone Carbonitrile inhibits the reaction [Lithocholic Acid results in increased expression of BCL2L1 mRNA] CTD PMID:19433268 progesterone increases expression EXP   6480464 Progesterone results in increased expression of BCL2L1 protein CTD PMID:15941375 propiconazole decreases expression ISO RGD:1552009 6480464 propiconazole results in decreased expression of BCL2L1 mRNA CTD PMID:21278054 prostaglandin E2 multiple interactions EXP   6480464 Dinoprostone affects the reaction [Puromycin Aminonucleoside results in decreased expression of BCL2L1 protein] CTD PMID:16396944 pterostilbene increases expression ISO RGD:1552009 6480464 pterostilbene results in increased expression of BCL2L1 protein CTD PMID:20681671 purine-6-thiol decreases expression ISO RGD:735516 6480464 6-Mercaptopurine results in decreased expression of BCL2L1 protein CTD PMID:12697733 puromycin multiple interactions ISO RGD:735516 6480464 Melatonin promotes the reaction [Puromycin results in decreased expression of BCL2L1 protein] CTD PMID:21244482 puromycin decreases expression ISO RGD:735516 6480464 Puromycin results in decreased expression of BCL2L1 protein CTD PMID:21244482 quercetin decreases expression ISO RGD:735516 6480464 Quercetin results in decreased expression of BCL2L1 protein CTD PMID:18787224 PMID:16049707 quercetin multiple interactions ISO RGD:735516 6480464 [arsenic trioxide co-treated with Quercetin] results in decreased expression of BCL2L1 protein CTD PMID:18359480 quercetin decreases expression ISO RGD:735516 6480464 Quercetin results in decreased expression of BCL2L1 protein CTD PMID:16049707 PMID:18787224 quercetin multiple interactions ISO RGD:1552009 6480464 Quercetin inhibits the reaction [CPG-oligonucleotide results in increased expression of BCL2L1 protein] CTD PMID:17046822 quercetin multiple interactions ISO RGD:735516 6480464 [Quercetin results in increased susceptibility to Cisplatin] which results in decreased expression of BCL2L1 protein CTD PMID:16619537 resveratrol multiple interactions ISO RGD:735516 6480464 resveratrol inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2L1 protein] CTD PMID:19620254 resveratrol multiple interactions ISO RGD:735516 6480464 resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 mRNA]; more ... CTD PMID:19047049 resveratrol decreases expression ISO RGD:735516 6480464 resveratrol results in decreased expression of BCL2L1 mRNA CTD PMID:20697895 PMID:20878097 resveratrol decreases expression ISO RGD:735516 6480464 resveratrol results in decreased expression of BCL2L1 protein CTD PMID:11577002 more ... resveratrol decreases response to substance ISO RGD:735516 6480464 BCL2L1 protein results in decreased susceptibility to resveratrol CTD PMID:19561642 resveratrol increases expression ISO RGD:735516 6480464 resveratrol results in increased expression of BCL2L1 mRNA CTD PMID:12569576 PMID:18089832 resveratrol increases expression ISO RGD:735516 6480464 resveratrol results in increased expression of BCL2L1 protein CTD PMID:18089832 resveratrol decreases expression ISO RGD:735516 6480464 resveratrol results in decreased expression of BCL2L1 protein CTD PMID:14749477 more ... resveratrol decreases expression ISO RGD:735516 6480464 resveratrol results in decreased expression of BCL2L1 mRNA CTD PMID:20878097 resveratrol multiple interactions ISO RGD:1552009 6480464 resveratrol inhibits the reaction [Nicotine results in decreased expression of BCL2L1 mRNA] CTD PMID:22687363 resveratrol decreases expression ISO RGD:735516 6480464 resveratrol results in decreased expression of BCL2L1 protein CTD PMID:14749477 more ... resveratrol decreases expression ISO RGD:735516 6480464 resveratrol results in decreased expression of BCL2L1 protein CTD PMID:17636462 more ... resveratrol decreases expression ISO RGD:735516 6480464 resveratrol results in decreased expression of BCL2L1 protein CTD PMID:17636462 more ... resveratrol decreases expression ISO RGD:735516 6480464 resveratrol results in decreased expression of BCL2L1 protein CTD PMID:14749477 more ... resveratrol decreases expression ISO RGD:735516 6480464 resveratrol results in decreased expression of BCL2L1 protein CTD PMID:17049120 more ... resveratrol affects localization EXP   6480464 resveratrol affects the localization of BCL2L1 protein CTD PMID:17984113 resveratrol multiple interactions ISO RGD:1552009 6480464 pifithrin inhibits the reaction [6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [resveratrol inhibits the reaction [Cisplatin results in decreased expression of BCL2L1]]]; more ... CTD PMID:21593185 resveratrol decreases expression ISO RGD:1552009 6480464 resveratrol results in decreased expression of BCL2L1 protein CTD PMID:17872969 resveratrol increases expression ISO RGD:735516 6480464 resveratrol results in increased expression of BCL2L1 mRNA CTD PMID:12569576 resveratrol decreases expression ISO RGD:735516 6480464 resveratrol results in decreased expression of BCL2L1 protein CTD PMID:17636462 more ... resveratrol multiple interactions ISO RGD:735516 6480464 resveratrol inhibits the reaction [STAT3 protein results in increased expression of BCL2L1 protein] CTD PMID:16546976 rifampicin increases expression ISO RGD:735516 6480464 Rifampin results in increased expression of BCL2L1 protein CTD PMID:11958592 PMID:12645856 rifampicin increases expression ISO RGD:735516 6480464 Rifampin results in increased expression of BCL2L1 protein CTD PMID:12645856 PMID:11958592 rifampicin multiple interactions ISO RGD:1552009 6480464 [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of BCL2L1 mRNA CTD PMID:21224054 Ro 31-8220 multiple interactions EXP   6480464 Ro 31-8220 inhibits the reaction [Lindane results in increased expression of BCL2L1 protein] CTD PMID:22001173 romidepsin multiple interactions ISO RGD:735516 6480464 [romidepsin co-treated with bortezomib] results in decreased expression of BCL2L1 protein CTD PMID:18223231 rosiglitazone increases expression ISO RGD:735516 6480464 rosiglitazone results in increased expression of BCL2L1 mRNA CTD PMID:17639046 scutellarin multiple interactions EXP   6480464 scutellarin inhibits the reaction [cobaltous chloride results in decreased expression of BCL2L1 mRNA] CTD PMID:18442013 selenium atom increases expression ISO RGD:735516 6480464 Selenium results in increased expression of BCL2L1 mRNA CTD PMID:19244175 selenium atom multiple interactions EXP   6480464 [Selenium deficiency co-treated with Vitamin E deficiency] results in decreased expression of BCL2L1 mRNA CTD PMID:11444866 sildenafil affects response to substance ISO RGD:735516 6480464 BCL2L1 protein affects the susceptibility to sildenafil CTD PMID:20884855 sildenafil multiple interactions ISO RGD:735516 6480464 sildenafil promotes the reaction [Doxorubicin results in decreased expression of BCL2L1 protein]; more ... CTD PMID:20884855 simvastatin decreases expression ISO RGD:735516 6480464 Simvastatin results in decreased expression of BCL2L1 protein CTD PMID:18521906 simvastatin decreases expression ISO RGD:735516 6480464 Simvastatin results in decreased expression of BCL2L1 protein CTD PMID:18521906 PMID:20060890 simvastatin decreases expression ISO RGD:735516 6480464 Simvastatin results in decreased expression of BCL2L1 protein CTD PMID:20060890 PMID:18521906 simvastatin multiple interactions ISO RGD:735516 6480464 Simvastatin inhibits the reaction [TNF protein results in increased expression of BCL2L1 protein] CTD PMID:17277159 sirolimus multiple interactions ISO RGD:735516 6480464 [7-hydroxystaurosporine co-treated with Sirolimus] results in decreased expression of BCL2L1 protein CTD PMID:15767555 sirolimus increases expression ISO RGD:1552009 6480464 Sirolimus results in increased expression of BCL2L1 protein CTD PMID:18097008 sirolimus increases expression ISO RGD:1552009 6480464 Sirolimus results in increased expression of BCL2L1 mRNA CTD PMID:21681844 sirolimus decreases expression ISO RGD:1552009 6480464 Sirolimus results in decreased expression of BCL2L1 mRNA; more ... CTD PMID:19922502 sirolimus multiple interactions ISO RGD:1552009 6480464 Sirolimus inhibits the reaction [Lipopolysaccharides results in increased expression of BCL2L1 protein] CTD PMID:18789402 sirolimus multiple interactions ISO RGD:1552009 6480464 [Sirolimus co-treated with IL2 protein] results in increased expression of BCL2L1 mRNA CTD PMID:11355896 sirolimus decreases expression ISO RGD:735516 6480464 Sirolimus results in decreased expression of BCL2L1 protein CTD PMID:15782132 sirolimus multiple interactions ISO RGD:735516 6480464 Sirolimus inhibits the reaction [Lipopolysaccharides results in increased expression of BCL2L1 protein] CTD PMID:18789402 sodium dichromate decreases expression ISO RGD:1552009 6480464 sodium bichromate results in decreased expression of BCL2L1 protein CTD PMID:21047991 sodium dichromate multiple interactions ISO RGD:1552009 6480464 CAT protein inhibits the reaction [sodium bichromate results in decreased expression of BCL2L1 protein]; more ... CTD PMID:20298709 sodium dichromate decreases expression ISO RGD:1552009 6480464 sodium bichromate results in decreased expression of BCL2L1 protein CTD PMID:20298709 PMID:21047991 spironolactone increases expression EXP   6480464 Spironolactone results in increased expression of BCL2L1 protein CTD PMID:19114643 staurosporine affects expression EXP   6480464 Staurosporine affects the expression of BCL2L1 mRNA CTD PMID:11296547 staurosporine increases expression ISO RGD:735516 6480464 Staurosporine results in increased expression of BCL2L1 protein alternative form CTD PMID:21256112 staurosporine decreases response to substance EXP   6480464 BCL2L1 gene mutant form results in decreased susceptibility to Staurosporine CTD PMID:10970895 staurosporine decreases response to substance ISO RGD:1552009 6480464 BCL2L1 protein results in decreased susceptibility to Staurosporine CTD PMID:10679475 staurosporine decreases response to substance ISO RGD:735516 6480464 BCL2L1 protein results in decreased susceptibility to Staurosporine CTD PMID:11468182 stavudine increases expression EXP   6480464 Stavudine results in increased expression of BCL2L1 mRNA CTD PMID:18299183 streptozocin increases expression EXP   6480464 Streptozocin results in increased expression of BCL2L1 protein CTD PMID:15976052 PMID:19682444 streptozocin multiple interactions EXP   6480464 cobaltiprotoporphyrin inhibits the reaction [Streptozocin results in decreased expression of BCL2L1 protein]; more ... CTD PMID:16595661 streptozocin decreases expression EXP   6480464 Streptozocin results in decreased expression of BCL2L1 protein CTD PMID:16595661 PMID:18758938 streptozocin multiple interactions EXP   6480464 Ascorbic Acid inhibits the reaction [Streptozocin results in decreased expression of BCL2L1 protein] CTD PMID:18758938 streptozocin decreases expression EXP   6480464 Streptozocin results in decreased expression of BCL2L1 protein CTD PMID:18758938 streptozocin multiple interactions EXP   6480464 arjunolic acid inhibits the reaction [Streptozocin results in increased expression of BCL2L1 protein] CTD PMID:19682444 styrene increases expression ISO RGD:735516 6480464 Styrene results in increased expression of BCL2L1 protein CTD PMID:16705669 styrene oxide increases expression ISO RGD:735516 6480464 styrene oxide results in increased expression of BCL2L1 protein CTD PMID:16705669 succimer multiple interactions ISO RGD:1552009 6480464 [Succimer binds to Magnetite Nanoparticles] which results in increased expression of BCL2L1 mRNA CTD PMID:21641980 sulforaphane decreases expression ISO RGD:735516 6480464 sulforafan results in decreased expression of BCL2L1 protein CTD PMID:16033772 sulforaphane decreases expression ISO RGD:1552009 6480464 sulforafan results in decreased expression of BCL2L1 protein CTD PMID:21684301 sulforaphane multiple interactions ISO RGD:1552009 6480464 sulforafan inhibits the reaction [sulforafan results in decreased expression of BCL2L1 protein] CTD PMID:21684301 sulindac multiple interactions ISO RGD:735516 6480464 Acetylcysteine inhibits the reaction [[Sulindac co-treated with arsenic trioxide] results in increased phosphorylation of BCL2L1 protein]; more ... CTD PMID:18281123 sulindac decreases expression ISO RGD:735516 6480464 Sulindac results in decreased expression of BCL2L1 protein CTD PMID:11062132 tacrolimus hydrate multiple interactions ISO RGD:1552009 6480464 Tacrolimus inhibits the reaction [Superantigens results in increased expression of BCL2L1 protein] CTD PMID:10532544 tamoxifen multiple interactions ISO RGD:735516 6480464 [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Tamoxifen] results in decreased expression of BCL2L1 mRNA; more ... CTD PMID:22046442 taurine multiple interactions EXP   6480464 Taurine inhibits the reaction [Acetaminophen results in increased expression of BCL2L1 protein modified form] CTD PMID:20166895 taurine multiple interactions EXP   6480464 Taurine inhibits the reaction [sodium arsenite results in increased expression of BCL2L1 protein alternative form] CTD PMID:20830294 taurine multiple interactions EXP   6480464 Taurine inhibits the reaction [Alloxan results in decreased expression of BCL2L1 protein] CTD PMID:22138235 taurine multiple interactions EXP   6480464 Taurine inhibits the reaction [sodium arsenite results in decreased expression of BCL2L1 protein] CTD PMID:19616567 temozolomide multiple interactions ISO RGD:735516 6480464 MGMT protein affects the reaction [BCL2L1 protein affects the susceptibility to temozolomide] CTD PMID:16405512 TEMPO multiple interactions EXP   6480464 TEMPO inhibits the reaction [Lindane results in increased expression of BCL2L1 protein] CTD PMID:22001173 tert-butyl hydroperoxide decreases expression ISO RGD:735516 6480464 tert-Butylhydroperoxide results in decreased expression of BCL2L1 mRNA CTD PMID:12419474 tert-butyl hydroperoxide decreases expression EXP   6480464 tert-Butylhydroperoxide results in decreased expression of BCL2L1 protein CTD PMID:15569404 tert-butyl hydroperoxide multiple interactions EXP   6480464 Curcumin inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of BCL2L1 protein] CTD PMID:15569404 tetrachloromethane multiple interactions ISO RGD:1552009 6480464 PPARD protein affects the reaction [Carbon Tetrachloride results in increased expression of BCL2L1 mRNA] CTD PMID:18038451 tetrachloromethane multiple interactions EXP   6480464 [N,N-dimethylformamide co-treated with Carbon Tetrachloride] results in decreased expression of BCL2L1 protein; more ... CTD PMID:20097184 tetrachloromethane increases expression EXP   6480464 Carbon Tetrachloride results in increased expression of BCL2L1 protein CTD PMID:16038630 tetrachloromethane decreases expression EXP   6480464 Carbon Tetrachloride results in decreased expression of BCL2L1 mRNA CTD PMID:19784758 tetrachloromethane multiple interactions EXP   6480464 [Carbon Tetrachloride co-treated with TM4SF4 protein] results in decreased expression of BCL2L1 mRNA CTD PMID:17069928 tetrachloromethane affects expression EXP   6480464 Carbon Tetrachloride affects the expression of BCL2L1 mRNA CTD PMID:12734012 thalidomide decreases expression ISO RGD:735516 6480464 Thalidomide results in decreased expression of BCL2L1 protein CTD PMID:15986355 thioacetamide decreases expression EXP   6480464 Thioacetamide results in decreased expression of BCL2L1 mRNA CTD PMID:19784758 titanium dioxide decreases expression ISO RGD:735516 6480464 titanium dioxide results in decreased expression of BCL2L1 mRNA CTD PMID:19486931 tocopherol decreases response to substance ISO RGD:735516 6480464 BCL2L1 protein results in decreased susceptibility to Tocopherols CTD PMID:16001965 topotecan multiple interactions ISO RGD:1552009 6480464 APAF1 promotes the reaction [Topotecan results in increased degradation of BCL2L1 protein]; more ... CTD PMID:19812371 topotecan increases degradation ISO RGD:1552009 6480464 Topotecan results in increased degradation of BCL2L1 protein CTD PMID:19812371 trans-resveratrol multiple interactions ISO RGD:735516 6480464 resveratrol inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2L1 protein] CTD PMID:19620254 trans-resveratrol multiple interactions ISO RGD:735516 6480464 resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 mRNA]; more ... CTD PMID:19047049 trans-resveratrol decreases expression ISO RGD:735516 6480464 resveratrol results in decreased expression of BCL2L1 mRNA CTD PMID:20697895 PMID:20878097 trans-resveratrol decreases expression ISO RGD:735516 6480464 resveratrol results in decreased expression of BCL2L1 protein CTD PMID:11577002 more ... trans-resveratrol decreases response to substance ISO RGD:735516 6480464 BCL2L1 protein results in decreased susceptibility to resveratrol CTD PMID:19561642 trans-resveratrol increases expression ISO RGD:735516 6480464 resveratrol results in increased expression of BCL2L1 mRNA CTD PMID:12569576 PMID:18089832 trans-resveratrol increases expression ISO RGD:735516 6480464 resveratrol results in increased expression of BCL2L1 protein CTD PMID:18089832 trans-resveratrol decreases expression ISO RGD:735516 6480464 resveratrol results in decreased expression of BCL2L1 protein CTD PMID:14749477 more ... trans-resveratrol decreases expression ISO RGD:735516 6480464 resveratrol results in decreased expression of BCL2L1 mRNA CTD PMID:20878097 trans-resveratrol multiple interactions ISO RGD:1552009 6480464 resveratrol inhibits the reaction [Nicotine results in decreased expression of BCL2L1 mRNA] CTD PMID:22687363 trans-resveratrol decreases expression ISO RGD:735516 6480464 resveratrol results in decreased expression of BCL2L1 protein CTD PMID:14749477 more ... trans-resveratrol decreases expression ISO RGD:735516 6480464 resveratrol results in decreased expression of BCL2L1 protein CTD PMID:17636462 more ... trans-resveratrol decreases expression ISO RGD:735516 6480464 resveratrol results in decreased expression of BCL2L1 protein CTD PMID:17636462 more ... trans-resveratrol decreases expression ISO RGD:735516 6480464 resveratrol results in decreased expression of BCL2L1 protein CTD PMID:14749477 more ... trans-resveratrol decreases expression ISO RGD:735516 6480464 resveratrol results in decreased expression of BCL2L1 protein CTD PMID:17049120 more ... trans-resveratrol multiple interactions ISO RGD:735516 6480464 resveratrol inhibits the reaction [STAT3 protein results in increased expression of BCL2L1 protein] CTD PMID:16546976 trans-resveratrol decreases expression ISO RGD:735516 6480464 resveratrol results in decreased expression of BCL2L1 protein CTD PMID:17636462 more ... trans-resveratrol increases expression ISO RGD:735516 6480464 resveratrol results in increased expression of BCL2L1 mRNA CTD PMID:12569576 trans-resveratrol decreases expression ISO RGD:1552009 6480464 resveratrol results in decreased expression of BCL2L1 protein CTD PMID:17872969 trans-resveratrol multiple interactions ISO RGD:1552009 6480464 pifithrin inhibits the reaction [6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [resveratrol inhibits the reaction [Cisplatin results in decreased expression of BCL2L1]]]; more ... CTD PMID:21593185 trans-resveratrol affects localization EXP   6480464 resveratrol affects the localization of BCL2L1 protein CTD PMID:17984113 trichloroethene multiple interactions EXP   6480464 [Benzene co-treated with methylmercury II co-treated with Trichloroethylene] results in increased expression of BCL2L1 mRNA CTD PMID:17905399 trichostatin A multiple interactions ISO RGD:735516 6480464 BCL2L1 protein results in decreased susceptibility to [bortezomib co-treated with trichostatin A]; more ... CTD PMID:16904634 trichostatin A decreases expression ISO RGD:735516 6480464 trichostatin A results in decreased expression of BCL2L1 protein CTD PMID:16009488 PMID:19887557 trichostatin A multiple interactions ISO RGD:735516 6480464 N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [SLC39A6 mutant form inhibits the reaction [trichostatin A results in decreased expression of BCL2L1 protein]]; more ... CTD PMID:19887557 trichostatin A decreases response to substance EXP   6480464 BCL2L1 gene mutant form results in decreased susceptibility to trichostatin A CTD PMID:10970895 trichostatin A decreases expression ISO RGD:735516 6480464 trichostatin A results in decreased expression of BCL2L1 protein CTD PMID:16009488 trichostatin A decreases response to substance ISO RGD:735516 6480464 BCL2L1 protein results in decreased susceptibility to trichostatin A CTD PMID:15781649 troglitazone decreases expression ISO RGD:735516 6480464 troglitazone results in decreased expression of BCL2L1 protein CTD PMID:12680223 troglitazone decreases expression ISO RGD:735516 6480464 troglitazone results in decreased expression of BCL2L1 mRNA CTD PMID:19631733 valproic acid multiple interactions ISO RGD:1552009 6480464 ABT-737 inhibits the reaction [BCL2L1 protein results in decreased susceptibility to Valproic Acid] CTD PMID:19060243 valproic acid increases expression ISO RGD:735516 6480464 Valproic Acid results in increased expression of BCL2L1 mRNA CTD PMID:19101580 valproic acid decreases response to substance ISO RGD:1552009 6480464 BCL2L1 protein results in decreased susceptibility to Valproic Acid CTD PMID:19060243 vincristine affects response to substance ISO RGD:735516 6480464 BCL2L1 protein affects the susceptibility to Vincristine CTD PMID:22178383 zerumbone decreases expression ISO RGD:735516 6480464 zerumbone results in decreased expression of BCL2L1 mRNA CTD PMID:16007145 zinc atom decreases expression ISO RGD:735516 6480464 Zinc results in decreased expression of BCL2L1 protein CTD PMID:16472982 zinc atom multiple interactions ISO RGD:735516 6480464 Zinc inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [SLC39A6 mutant form inhibits the reaction [trichostatin A results in decreased expression of BCL2L1 protein]]] CTD PMID:19887557 zinc atom increases expression EXP   6480464 Zinc results in increased expression of BCL2L1 mRNA CTD PMID:17074742 zinc dichloride multiple interactions ISO RGD:735516 6480464 [Citric Acid co-treated with zinc chloride] results in decreased expression of BCL2L1 protein CTD PMID:16624386 zinc pyrithione decreases expression ISO RGD:735516 6480464 zinc pyrithione results in decreased expression of BCL2L1 mRNA CTD PMID:21424779 zinc sulfate increases expression EXP   6480464 Zinc Sulfate results in increased expression of BCL2L1 mRNA CTD PMID:17074742 zinc(0) decreases expression ISO RGD:735516 6480464 Zinc results in decreased expression of BCL2L1 protein CTD PMID:16472982 zinc(0) multiple interactions ISO RGD:735516 6480464 Zinc inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [SLC39A6 mutant form inhibits the reaction [trichostatin A results in decreased expression of BCL2L1 protein]]] CTD PMID:19887557 zinc(0) increases expression EXP   6480464 Zinc results in increased expression of BCL2L1 mRNA CTD PMID:17074742 zoledronic acid increases expression ISO RGD:735516 6480464 zoledronic acid results in increased expression of BCL2L1 mRNA CTD PMID:19036117 Gene Ontology Annotations Biological Process Term Qualifier Evidence With Reference Notes Source Original Reference(s) apoptotic process   IEP   2314140   RGD   apoptotic process   ISO RGD:1552009 1624291 MGI:MGI:107739 RGD MGI:MGI:1351384 PMID:10618441 apoptotic process   ISO RGD:1552009 1624291 MGI:MGI:2183839|PMID:12115603 RGD MGI:MGI:2183839 PMID:12115603 cell proliferation   ISO RGD:1552009 1624291 MGI:MGI:892190|PMID:9176392 RGD MGI:MGI:892190 PMID:9176392 cellular process regulating host cell cycle in response to virus   ISO RGD:1552009 1624291 MGI:MGI:2675966 RGD MGI:MGI:3057092 PMID:15231831 cellular response to alkaloid   ISO RGD:1552009 1624291 MGI:MGI:3057092|PMID:15231831 RGD MGI:MGI:3057092 PMID:15231831 cellular response to amino acid stimulus   ISO RGD:1552009 1624291 MGI:MGI:2675966 RGD MGI:MGI:3057092 PMID:15231831 cellular response to gamma radiation   ISO RGD:1552009 1624291 MGI:MGI:3057092|PMID:15231831 RGD MGI:MGI:3057092 PMID:15231831 cytokinesis   ISO RGD:735516 1624291 PMID:21840391 RGD PMID:21840391 cytokinesis   ISS UniProtKB:Q07817 1600115 GO_REF:0000024 UniProtKB GO_REF:0000024 fertilization   ISO RGD:1552009 1624291 MGI:MGI:99702 RGD MGI:MGI:1860555 PMID:10894153 germ cell development   ISO RGD:1552009 1624291 MGI:MGI:2176699 RGD MGI:MGI:1860555 PMID:10894153 growth   ISO RGD:1552009 1624291 MGI:MGI:2176699 RGD MGI:MGI:1860555 PMID:10894153 in utero embryonic development   ISO RGD:1552009 1624291 MGI:MGI:2158303 RGD MGI:MGI:1351384 PMID:10618441 male gonad development   ISO RGD:1552009 1624291 MGI:MGI:2176699 RGD MGI:MGI:1860555 PMID:10894153 mitotic cell cycle checkpoint   ISO RGD:735516 1624291 PMID:21840391 RGD PMID:21840391 mitotic cell cycle checkpoint   ISS UniProtKB:Q07817 1600115 GO_REF:0000024 UniProtKB GO_REF:0000024 negative regulation of anoikis   ISO RGD:735516 1624291 PMID:15006356 RGD PMID:15006356 negative regulation of apoptotic process   IDA   628531   RGD   negative regulation of apoptotic process   ISO RGD:735516 1624291 PMID:9388232 RGD PMID:9388232 negative regulation of apoptotic process   ISO RGD:735516 1624291 PMID:20673843 RGD PMID:20673843 negative regulation of apoptotic process   ISO RGD:735516 1624291 PMID:12011449 RGD PMID:12011449 negative regulation of apoptotic process   ISO RGD:735516 1624291 PMID:16608847 RGD PMID:16608847 negative regulation of apoptotic process   ISO RGD:1552009 1624291 MGI:MGI:3689797|PMID:15901672 RGD MGI:MGI:3689797 PMID:15901672 negative regulation of apoptotic process   ISO RGD:1552009 1624291 MGI:MGI:3700106|PMID:17267035 RGD MGI:MGI:3700106 PMID:17267035 negative regulation of apoptotic process   ISO RGD:1552009 1624291 MGI:MGI:69011|PMID:7607090 RGD MGI:MGI:69011 PMID:7607090 negative regulation of apoptotic process   ISO RGD:1552009 1624291 MGI:MGI:2158953|PMID:11717309 RGD MGI:MGI:2158953 PMID:11717309 negative regulation of apoptotic process   ISO RGD:735516 1624291 PMID:21567405 RGD PMID:21567405 negative regulation of apoptotic process   ISO RGD:735516 1624291 PMID:17289999 RGD PMID:17289999 negative regulation of apoptotic process   ISO RGD:735516 1624291 PMID:7650367 RGD PMID:7650367 negative regulation of apoptotic process   ISO RGD:735516 1624291 PMID:15231831 RGD PMID:15231831 negative regulation of apoptotic process   ISO RGD:1552009 1624291 MGI:MGI:2158303 RGD MGI:MGI:1351384 PMID:10618441 negative regulation of apoptotic process   ISO RGD:1552009 1624291 MGI:MGI:81233|PMID:8798158 RGD MGI:MGI:81233 PMID:8798158 negative regulation of apoptotic process   ISO RGD:1552009 1624291 MGI:MGI:99702 RGD MGI:MGI:82784 PMID:8798452 negative regulation of apoptotic process   ISO RGD:1552009 1624291 MGI:MGI:2677658|PMID:14517295 RGD MGI:MGI:2677658 PMID:14517295 negative regulation of apoptotic process   ISO RGD:1552009 1624291 MGI:MGI:1326944|PMID:9867803 RGD MGI:MGI:1326944 PMID:9867803 negative regulation of apoptotic process   ISO RGD:1552009 1624291 MGI:MGI:2176699 RGD MGI:MGI:1860555 PMID:10894153 negative regulation of apoptotic process   IDA   631757   RGD   negative regulation of cysteine-type endopeptidase activity involved in apoptotic process   IDA   628531 PMID:12097494 GOC   negative regulation of establishment of protein localization to plasma membrane   ISO RGD:735516 1624291 PMID:21041309 RGD PMID:21041309 negative regulation of intrinsic apoptotic signaling pathway   ISO RGD:735516 1624291 PMID:21567405 RGD PMID:21567405 negative regulation of neuron apoptotic process   ISO RGD:1552009 1624291 MGI:MGI:2158303 RGD MGI:MGI:1929535 PMID:11150333 negative regulation of neuron apoptotic process   ISO RGD:1552009 1624291 MGI:MGI:99702 RGD MGI:MGI:86927 PMID:9096145 negative regulation of neuron apoptotic process   ISO RGD:1552009 1624291 MGI:MGI:72933|PMID:7753802 RGD MGI:MGI:72933 PMID:7753802 negative regulation of neuron apoptotic process   ISO RGD:1552009 1624291 MGI:MGI:79659|PMID:8625820 RGD MGI:MGI:79659 PMID:8625820 negative regulation of neuron apoptotic process   ISO RGD:1552009 1624291 MGI:MGI:2675966 RGD MGI:MGI:3057092 PMID:15231831 negative regulation of release of cytochrome c from mitochondria   ISO RGD:735516 1624291 PMID:12667443 RGD PMID:12667443 ovarian follicle development   ISO RGD:1552009 1624291 MGI:MGI:2176699 RGD MGI:MGI:1860555 PMID:10894153 ovarian follicle development   IMP   1643337   RGD   positive regulation of apoptotic process   ISO RGD:1552009 1624291 MGI:MGI:81233|PMID:8798158 RGD MGI:MGI:81233 PMID:8798158 positive regulation of cell proliferation   ISO RGD:1552009 1624291 MGI:MGI:3700106|PMID:17267035 RGD MGI:MGI:3700106 PMID:17267035 regulation of apoptotic process   IDA   631757   RGD   regulation of apoptotic process   IEA InterPro:IPR002475|InterPro:IPR003093|InterPro:IPR013279|InterPro:IPR020717|InterPro:IPR020728|InterPro:IPR020731|InterPro:IPR026298 1600115 GO_REF:0000002 InterPro GO_REF:0000002 regulation of mitochondrial membrane permeability   ISO RGD:735516 1624291 PMID:9843949 RGD PMID:9843949 regulation of mitochondrial membrane potential   ISO RGD:735516 1624291 PMID:9843949 RGD PMID:9843949 release of cytochrome c from mitochondria   ISO RGD:1552009 1624291 MGI:MGI:99702 RGD MGI:MGI:3688960 PMID:17052454 release of cytochrome c from mitochondria   ISO RGD:735516 1624291 PMID:9843949 RGD PMID:9843949 response to cycloheximide   ISO RGD:1552009 1624291 MGI:MGI:892190|PMID:9176392 RGD MGI:MGI:892190 PMID:9176392 response to cytokine stimulus   ISO RGD:735516 1624291 PMID:9184696 RGD PMID:9184696 response to hydrogen peroxide   IEP   1643488   RGD   response to hypoxia   IEP   1643524   RGD   response to inorganic substance   IEP   1643484   RGD   response to lead ion   IEP   1643487   RGD   response to organic cyclic compound   IEP   1643489   RGD   response to organic nitrogen   IEP   1643485   RGD   response to oxidative stress   IEP   730278   RGD   response to peptide hormone stimulus   IEP   1643490   RGD   response to radiation   ISO RGD:1552009 1624291 MGI:MGI:2677658|PMID:14517295 RGD MGI:MGI:2677658 PMID:14517295 response to stress   IEP   1643492   RGD   response to virus   ISO RGD:1552009 1624291 MGI:MGI:3057092|PMID:15231831 RGD MGI:MGI:3057092 PMID:15231831 spermatogenesis   ISO RGD:1552009 1624291 MGI:MGI:99702 RGD MGI:MGI:1860555 PMID:10894153 Cellular Component Term Qualifier Evidence With Reference Notes Source Original Reference(s) Bcl-2 family protein complex   ISO RGD:735516 1624291 PMID:21199865 RGD PMID:21199865 centrosome   ISO RGD:735516 1624291 PMID:21840391 RGD PMID:21840391 centrosome   ISS UniProtKB:Q07817 1600115 GO_REF:0000024 UniProtKB GO_REF:0000024 cytoplasm   ISO RGD:735516 1624291 PMID:20673843 RGD PMID:20673843 cytosol   ISO RGD:1552009 1624291 MGI:MGI:2178871|PMID:11980919 RGD MGI:MGI:2178871 PMID:11980919 integral to membrane   IEA UniProtKB-KW:KW-0812 1600115 GO_REF:0000037 UniProtKB GO_REF:0000037 intracellular   ISO RGD:1552009 1624291 MGI:MGI:1928555|PMID:11146504 RGD MGI:MGI:1928555 PMID:11146504 mitochondrial envelope   IDA   628531   RGD   mitochondrial membrane   ISO RGD:1552009 1624291 MGI:MGI:2178871|PMID:11980919 RGD MGI:MGI:2178871 PMID:11980919 mitochondrial outer membrane   IDA   631757   RGD   mitochondrial part   ISO RGD:1552009 1624291 MGI:MGI:69011|PMID:7607090 RGD MGI:MGI:69011 PMID:7607090 mitochondrion   ISO RGD:1552009 1624291 MGI:MGI:2682130|PMID:14651853 RGD MGI:MGI:2682130 PMID:14651853 mitochondrion   ISO RGD:735516 1624291 PMID:12011449 RGD PMID:12011449 mitochondrion   ISO RGD:1552009 1624291 MGI:MGI:2671672|PMID:12931191 RGD MGI:MGI:2671672 PMID:12931191 nuclear membrane   IEA UniProtKB-SubCell:SL-0182 1600115 GO_REF:0000039 UniProtKB GO_REF:0000039 Molecular Function Term Qualifier Evidence With Reference Notes Source Original Reference(s) BH domain binding   IPI RGD:2192 70678   RGD   BH domain binding   IPI RGD:621547 70678   RGD   BH domain binding   IPI RGD:621635 70678   RGD   BH3 domain binding   ISO RGD:735516 1624291 UniProtKB:Q16611 RGD PMID:15901672 cysteine-type endopeptidase inhibitor activity involved in apoptotic process   IDA   628531   RGD   identical protein binding   ISO RGD:735516 1624291 UniProtKB:Q07817-1 RGD PMID:15131699 MDM2/MDM4 family protein binding   IPI RGD:1305332 2317383   RGD   protein binding   IPI RGD:620103 1579942   RGD   protein binding   ISO RGD:735516 1624291 UniProtKB:O43521 RGD PMID:23245996 protein binding   ISO RGD:735516 1624291 UniProtKB:O00198 RGD PMID:15031724 protein binding   ISO RGD:1552009 1624291 UniProtKB:E9QM21 RGD MGI:MGI:3804133 PMID:16705087 protein binding   IPI UniProtKB:O35303   PMID:18250306 IntAct PMID:18250306 protein binding   ISO RGD:735516 1624291 UniProtKB:Q9NYF8 RGD PMID:10837489 protein binding   ISO RGD:735516 1624291 UniProtKB:Q92934 RGD PMID:20603619 protein binding   ISO RGD:735516 1624291 UniProtKB:Q92934 RGD PMID:19667065 protein binding   ISO RGD:735516 1624291 UniProtKB:O00198 RGD PMID:15694340 protein binding   ISO RGD:735516 1624291 UniProtKB:Q92934 RGD PMID:15131699 protein binding   ISO RGD:735516 1624291 UniProtKB:Q07812 RGD PMID:9388232 protein binding   ISO RGD:735516 1624291 UniProtKB:P30429 RGD PMID:9027313 protein binding   ISO RGD:735516 1624291 UniProtKB:P30429 RGD PMID:9027312 protein binding   ISO RGD:735516 1624291 UniProtKB:Q16611 RGD PMID:22516262 protein binding   ISO RGD:735516 1624291 UniProtKB:Q07812 RGD PMID:21671007 protein binding   ISO RGD:735516 1624291 UniProtKB:Q07812 RGD PMID:21567405 protein binding   ISO RGD:735516 1624291 UniProtKB:Q07812 RGD PMID:21458670 protein binding   ISO RGD:735516 1624291 UniProtKB:Q07812 RGD PMID:21199865 protein binding   ISO RGD:735516 1624291 UniProtKB:Q92934 RGD PMID:21081150 protein binding   ISO RGD:735516 1624291 UniProtKB:P63244 RGD PMID:20541605 protein binding   ISO RGD:735516 1624291 UniProtKB:Q8N5K1 RGD PMID:20010695 protein binding   ISO RGD:735516 1624291 UniProtKB:Q07812 RGD PMID:19074440 protein binding   ISO RGD:735516 1624291 UniProtKB:Q16611 RGD PMID:19060904 protein binding   ISO RGD:735516 1624291 UniProtKB:Q16611 RGD PMID:17446862 protein binding   ISO RGD:735516 1624291 UniProtKB:Q9C000 RGD PMID:17418785 protein binding   ISO RGD:735516 1624291 UniProtKB:Q07812 RGD PMID:17289999 protein binding   ISO RGD:735516 1624291 UniProtKB:Q13323 RGD PMID:16697956 protein binding   ISO RGD:735516 1624291 UniProtKB:Q07812 RGD PMID:16608847 protein binding   ISO RGD:735516 1624291 UniProtKB:Q13323 RGD PMID:16189514 protein binding   ISO RGD:735516 1624291 UniProtKB:P02340 RGD PMID:16151013 protein binding   ISO RGD:735516 1624291 UniProtKB:Q16611 RGD PMID:15901672 protein binding   ISO RGD:735516 1624291 UniProtKB:Q14296 RGD PMID:15110758 protein binding   ISO RGD:735516 1624291 UniProtKB:P04637 RGD PMID:14963330 protein binding   ISO RGD:735516 1624291 UniProtKB:P02489 RGD PMID:14752512 protein binding   ISO RGD:735516 1624291 UniProtKB:O15304 RGD PMID:14739602 protein binding   ISO RGD:735516 1624291 UniProtKB:Q16611 RGD PMID:14596824 protein binding   ISO RGD:735516 1624291 UniProtKB:Q9H2V7 RGD PMID:12815463 protein binding   ISO RGD:735516 1624291 UniProtKB:P04637 RGD PMID:12667443 protein binding   ISO RGD:735516 1624291 UniProtKB:O15304-1 RGD PMID:12011449 protein binding   ISO RGD:735516 1624291 UniProtKB:Q99638 RGD PMID:11971963 protein binding   ISO RGD:735516 1624291 UniProtKB:Q9UKT9 RGD PMID:11714801 protein binding   ISO RGD:735516 1624291 UniProtKB:Q9BXH1 RGD PMID:11463391 protein binding   ISO RGD:735516 1624291 UniProtKB:Q9HD36 RGD PMID:11278245 protein binding   ISO RGD:735516 1624291 UniProtKB:Q9NQC3 RGD PMID:11126360 protein binding   ISO RGD:735516 1624291 UniProtKB:Q96BY2 RGD PMID:11060313 protein binding   ISO RGD:735516 1624291 UniProtKB:Q9BZR8 RGD PMID:11054413 protein binding   IPI RGD:70549 70327   RGD   protein binding   ISO RGD:735516 1624291 UniProtKB:Q86Y07-1 RGD PMID:23449449 protein binding   ISO RGD:1552009 1624291 UniProtKB:Q61337 RGD MGI:MGI:3778846 PMID:18223655 protein binding   ISO RGD:1552009 1624291 UniProtKB:Q61337 RGD MGI:MGI:5009772 PMID:21095239 protein heterodimerization activity   ISO RGD:1552009 1624291 UniProtKB:Q61337|UniProtKB:Q07813 RGD MGI:MGI:1095590 PMID:7834748 protein heterodimerization activity   IPI RGD:621547 70678   RGD   protein heterodimerization activity   IPI RGD:621635 70678   RGD   protein heterodimerization activity   IPI RGD:2192 70678   RGD   protein heterodimerization activity   ISO RGD:1552009 1624291 UniProtKB:Q07813 RGD MGI:MGI:82784 PMID:8798452 protein heterodimerization activity   ISO RGD:1552009 1624291 UniProtKB:Q07813 RGD MGI:MGI:2385423 PMID:7650488 protein kinase binding   ISO RGD:735516 1624291 UniProtKB:Q9H4B4 RGD PMID:21840391 Molecular Pathway Annotations Term Qualifier Evidence With Reference Notes Source Original Reference(s) amyotrophic lateral sclerosis disease pathway   IEA rno:05030 6907045   KEGG rno:05014 apoptotic cell death pathway   IEA RGD:2200 6907045   KEGG rno:04210 ceramide signaling pathway   IEA RGD:2200 6907045   KEGG rno:05212 chronic myeloid leukemia pathway   IEA RGD:2200 6907045   KEGG rno:05220 erythropoietin signaling pathway   ISO RGD:735516 6484113   PID PID:200183 interleukin-3 signaling pathway   ISO RGD:735516 6484113   PID PID:200145 intrinsic apoptotic pathway   IEP   2314140   RGD   intrinsic apoptotic pathway   ISS RGD:735516 2313975   RGD   intrinsic apoptotic pathway   ISS RGD:1552009 1579966   RGD   Jak-Stat signaling pathway   IEA RGD:2200 6907045   KEGG rno:04630 pancreatic cancer pathway   IEA RGD:2200 6907045   KEGG rno:05212 small cell lung cancer pathway   IEA RGD:2200 6907045   KEGG rno:05222 Toxoplasma gondii infection pathway   IEA RGD:2200 6907045   KEGG rno:05145 External Database Links KEGG Pathway Amyotrophic lateral sclerosis (ALS) Apoptosis Chronic myeloid leukemia HTLV-I infection Jak-STAT signaling pathway NF-kappa B signaling pathway Pancreatic cancer Pathways in cancer PI3K-Akt signaling pathway Small cell lung cancer Toxoplasmosis Transcriptional misregulation in cancer Pathway Interaction Database EPO signaling pathway (PID:200183) IL2 signaling events mediated by PI3K (PID:200118) IL2 signaling events mediated by STAT5 (PID:200184) IL3-mediated signaling events (PID:200145) Disease Annotations Brain Ischemia  (IEP) Breast Neoplasms  (ISS) Carcinoma, Renal Cell  (ISS) Carcinoma, Transitional Cell  (ISS) Diabetes Mellitus, Experimental  (IED) Endometrial Neoplasms  (ISS) Erectile Dysfunction  (IED) Leiomyoma  (ISS) Myocardial Infarction  (IPM) Ocular Hypertension  (IEP) Ovarian Neoplasms  (ISS) Prostatic Neoplasms  (ISS) Shock, Hemorrhagic  (IEP) Urinary Bladder Neoplasms  (ISS) Uterine Cervical Neoplasms  (ISS) Uterine Neoplasms  (ISS) Wilms Tumor  (ISS) Gene-Chemical Interaction Annotations (+)-alpha-tocopherol  (EXP) (-)-epigallocatechin 3-gallate  (ISO) (R)-carnitine  (EXP) (R)-mevalonic acid  (EXP) (R)-noradrenaline  (EXP) (S)-amphetamine  (EXP) (S)-colchicine  (EXP) (S)-nicotine  (ISO) 1'-acetoxychavicol acetate  (ISO) 1,3-dinitrobenzene  (EXP,ISO) 17beta-estradiol  (EXP,ISO) 17beta-hydroxy-5alpha-androstan-3-one  (EXP,ISO) 2,3,7,8-tetrachlorodibenzodioxine  (EXP,ISO) 2,4-dinitrotoluene  (EXP) 2,6-dichloroindophenol  (ISO) 2-acetamidofluorene  (EXP,ISO) 2-amino-2-deoxy-D-glucopyranose  (ISO) 2-deoxy-D-glucose  (ISO) 2-ethoxyethanol  (EXP) 2-methoxyethanol  (EXP) 3'-amino-3'-deoxy-N(6),N(6)-dimethyladenosine  (EXP,ISO) 3,3',5-triiodo-L-thyronine  (EXP,ISO) 3,3'-diindolylmethane  (ISO) 3,4-methylenedioxymethamphetamine  (EXP) 3-methyladenine  (ISO) 3-nitropropanoic acid  (EXP) 4-hydroxynon-2-enal  (ISO) 4-hydroxyphenyl retinamide  (ISO) 4-vinylcyclohexene dioxide  (ISO) 5-aza-2'-deoxycytidine  (ISO) 5-azacytidine  (ISO) 5-fluorouracil  (ISO) acetylsalicylic acid  (ISO) actinomycin D  (ISO) adenosine  (ISO) afimoxifene  (ISO) aflatoxin B1  (ISO) aldehydo-D-glucosamine  (ISO) all-trans-retinoic acid  (ISO) aluminium oxide  (ISO) ammonium chloride  (EXP) arachidonic acid  (ISO) arsenic atom  (EXP,ISO) atrazine  (ISO) azadirachtin A  (ISO) azathioprine  (ISO) benzene  (EXP) benzo[a]pyrene  (ISO) benzo[b]fluoranthene  (ISO) berberine  (ISO) beta-D-glucosamine  (ISO) bilirubin  (ISO) biochanin A  (ISO) bisphenol A  (ISO) brassinolide  (ISO) C60 fullerene  (EXP) cadmium dichloride  (ISO) calciol  (ISO) calcitriol  (EXP,ISO) camptothecin  (EXP) capsaicin  (ISO) carboplatin  (EXP,ISO) carmustine  (EXP,ISO) carvedilol  (EXP) cefaloridine  (EXP) celecoxib  (ISO) cetrorelix  (ISO) chloroquine  (ISO) chlorpromazine  (ISO) chlorpyrifos  (ISO) chrysazin  (ISO) ciguatoxin CTX1B  (ISO) cisplatin  (EXP,ISO) citric acid  (ISO) clofibrate  (ISO) clonidine  (EXP) clonidine (amino form)  (EXP) clonidine (imino form)  (EXP) cobalt dichloride  (EXP) cocaine  (EXP) copper atom  (EXP) copper(0)  (EXP) cordycepin  (ISO) corticosterone  (EXP) crocidolite asbestos  (EXP,ISO) curcumin  (EXP,ISO) cycloheximide  (ISO) cyclophosphamide  (EXP) cyclosporin A  (ISO) cypermethrin  (EXP) cytarabine  (ISO) D-glucose  (EXP) daidzein  (ISO) dasatinib (anhydrous)  (ISO) dehydroepiandrosterone  (EXP) dehydroepiandrosterone sulfate  (EXP) dexamethasone  (EXP,ISO) diarsenic trioxide  (EXP,ISO) diazoxide  (EXP,ISO) dibenz[a,h]anthracene  (ISO) dibenzo[a,l]pyrene  (ISO) diclofenac  (ISO) diethylstilbestrol  (ISO) dimethylarsinic acid  (ISO) dioxygen  (EXP,ISO) dipyridamole  (ISO) docetaxel anhydrous  (ISO) doxorubicin  (EXP,ISO) doxycycline  (ISO) elemental selenium  (EXP,ISO) endosulfan  (ISO) esculetin  (ISO) ethanol  (EXP) etoposide  (ISO) eugenol  (ISO) fenofibrate  (ISO) fluoxetine  (EXP) flutamide  (ISO) folic acid  (ISO) fucoxanthin  (ISO) furan  (EXP) gamma-hexachlorocyclohexane  (EXP) geldanamycin  (ISO) genistein  (ISO) glucose  (EXP) glutathione  (ISO) haloperidol  (EXP) hyaluronic acid  (ISO) hydrogen peroxide  (EXP,ISO) hydroxyurea  (EXP) ibuprofen  (ISO) imatinib  (ISO) indole-3-methanol  (ISO) indomethacin  (EXP,ISO) iron atom  (ISO) isoliquiritigenin  (ISO) isoprenaline  (EXP,ISO) isotretinoin  (ISO) kaempferol  (ISO) L-ascorbic acid  (EXP) lactacystin  (ISO) lansoprazole  (EXP) leptomycin B  (ISO) lithium chloride  (ISO) lithocholic acid  (ISO) lonidamine  (ISO) lovastatin  (EXP) lutein  (ISO) luteolin  (ISO) LY294002  (ISO) maneb  (ISO) mangiferin  (ISO) melamine  (ISO) melatonin  (EXP,ISO) mercaptopurine  (ISO) metformin  (ISO) methamphetamine  (EXP) methoxychlor  (ISO) methylmercury(1+)  (EXP) metoprolol  (EXP) mevalonic acid  (EXP) mifepristone  (EXP) mitomycin C  (ISO) mitoxantrone  (ISO) mono(2-ethylhexyl) phthalate  (ISO) monocrotaline  (ISO) morphine  (EXP) N,N-dimethylformamide  (EXP) N-acetyl-L-cysteine  (EXP,ISO) N-methyl-N'-nitro-N-nitrosoguanidine  (ISO) N-nitrosodiethylamine  (EXP,ISO) N-nitrosodimethylamine  (EXP) NAD zwitterion  (ISO) NAD(+)  (ISO) nickel dichloride  (EXP,ISO) nickel sulfate  (ISO) nitric oxide  (ISO) nitroprusside  (EXP) ochratoxin A  (EXP,ISO) oxaliplatin  (ISO) paclitaxel  (ISO) paracetamol  (EXP,ISO) paraquat  (EXP,ISO) parathion  (EXP) perindopril  (EXP) phenethyl isothiocyanate  (ISO) phenobarbital  (EXP,ISO) phenylephrine  (EXP) phenytoin  (ISO) phorbol 13-acetate 12-myristate  (ISO) pirinixic acid  (ISO) potassium dichromate  (EXP) pregnenolone 16alpha-carbonitrile  (ISO) progesterone  (EXP) propiconazole  (ISO) prostaglandin E2  (EXP) pterostilbene  (ISO) purine-6-thiol  (ISO) puromycin  (ISO) quercetin  (ISO) resveratrol  (EXP,ISO) rifampicin  (ISO) Ro 31-8220  (EXP) romidepsin  (ISO) rosiglitazone  (ISO) scutellarin  (EXP) selenium atom  (EXP,ISO) sildenafil  (ISO) simvastatin  (ISO) sirolimus  (ISO) sodium dichromate  (ISO) spironolactone  (EXP) staurosporine  (EXP,ISO) stavudine  (EXP) streptozocin  (EXP) styrene  (ISO) styrene oxide  (ISO) succimer  (ISO) sulforaphane  (ISO) sulindac  (ISO) tacrolimus hydrate  (ISO) tamoxifen  (ISO) taurine  (EXP) temozolomide  (ISO) TEMPO  (EXP) tert-butyl hydroperoxide  (EXP,ISO) tetrachloromethane  (EXP,ISO) thalidomide  (ISO) thioacetamide  (EXP) titanium dioxide  (ISO) tocopherol  (ISO) topotecan  (ISO) trans-resveratrol  (EXP,ISO) trichloroethene  (EXP) trichostatin A  (EXP,ISO) troglitazone  (ISO) valproic acid  (ISO) vincristine  (ISO) zerumbone  (ISO) zinc atom  (EXP,ISO) zinc dichloride  (ISO) zinc pyrithione  (ISO) zinc sulfate  (EXP) zinc(0)  (EXP,ISO) zoledronic acid  (ISO) Gene Ontology Annotations Biological Process apoptotic process  (IEP,ISO) cell proliferation  (ISO) cellular process regulating host cell cycle in response to virus  (ISO) cellular response to alkaloid  (ISO) cellular response to amino acid stimulus  (ISO) cellular response to gamma radiation  (ISO) cytokinesis  (ISO,ISS) fertilization  (ISO) germ cell development  (ISO) growth  (ISO) in utero embryonic development  (ISO) male gonad development  (ISO) mitotic cell cycle checkpoint  (ISO,ISS) negative regulation of anoikis  (ISO) negative regulation of apoptotic process  (IDA,ISO) negative regulation of cysteine-type endopeptidase activity involved in apoptotic process  (IDA) negative regulation of establishment of protein localization to plasma membrane  (ISO) negative regulation of intrinsic apoptotic signaling pathway  (ISO) negative regulation of neuron apoptotic process  (ISO) negative regulation of release of cytochrome c from mitochondria  (ISO) ovarian follicle development  (IMP,ISO) positive regulation of apoptotic process  (ISO) positive regulation of cell proliferation  (ISO) regulation of apoptotic process  (IDA,IEA) regulation of mitochondrial membrane permeability  (ISO) regulation of mitochondrial membrane potential  (ISO) release of cytochrome c from mitochondria  (ISO) response to cycloheximide  (ISO) response to cytokine stimulus  (ISO) response to hydrogen peroxide  (IEP) response to hypoxia  (IEP) response to inorganic substance  (IEP) response to lead ion  (IEP) response to organic cyclic compound  (IEP) response to organic nitrogen  (IEP) response to oxidative stress  (IEP) response to peptide hormone stimulus  (IEP) response to radiation  (ISO) response to stress  (IEP) response to virus  (ISO) spermatogenesis  (ISO) Cellular Component Bcl-2 family protein complex  (ISO) centrosome  (ISO,ISS) cytoplasm  (ISO) cytosol  (ISO) integral to membrane  (IEA) intracellular  (ISO) mitochondrial envelope  (IDA) mitochondrial membrane  (ISO) mitochondrial outer membrane  (IDA) mitochondrial part  (ISO) mitochondrion  (ISO) nuclear membrane  (IEA) Molecular Function BH domain binding  (IPI) BH3 domain binding  (ISO) cysteine-type endopeptidase inhibitor activity involved in apoptotic process  (IDA) identical protein binding  (ISO) MDM2/MDM4 family protein binding  (IPI) protein binding  (IPI,ISO) protein heterodimerization activity  (IPI,ISO) protein kinase binding  (ISO) Molecular Pathway Annotations amyotrophic lateral sclerosis disease pathway  (IEA) apoptotic cell death pathway  (IEA) ceramide signaling pathway  (IEA) chronic myeloid leukemia pathway  (IEA) erythropoietin signaling pathway  (ISO) interleukin-3 signaling pathway  (ISO) intrinsic apoptotic pathway  (IEP,ISS) Jak-Stat signaling pathway  (IEA) pancreatic cancer pathway  (IEA) small cell lung cancer pathway  (IEA) Toxoplasma gondii infection pathway  (IEA) External Database Links KEGG Pathway Amyotrophic lateral sclerosis (ALS) Apoptosis Chronic myeloid leukemia HTLV-I infection Jak-STAT signaling pathway NF-kappa B signaling pathway Pancreatic cancer Pathways in cancer PI3K-Akt signaling pathway Small cell lung cancer Toxoplasmosis Transcriptional misregulation in cancer Pathway Interaction Database EPO signaling pathway (PID:200183) IL2 signaling events mediated by PI3K (PID:200118) IL2 signaling events mediated by STAT5 (PID:200184) IL3-mediated signaling events (PID:200145) References - curated 1. Abe T, etal., Brain Res. 2004 May 29;1009(1-2):159-68. 2. Adams JM and Cory S, Oncogene. 2007 Feb 26;26(9):1324-37. 3. Arakawa M, etal., Life Sci. 2007 May 8;80(22):2076-84. Epub 2007 Apr 1. 4. Basta-Jovanovic G, etal., Ren Fail. 2005;27(1):13-8. 5. Bolenz C, etal., Urol Oncol. 2007 Nov-Dec;25(6):476-82. 6. Cao G, etal., J Neurosci 2002 Jul 1;22(13):5423-31. 7. Carlson DE, etal., Shock. 2007 Feb;27(2):192-8. 8. Chao SL, etal., J Biochem Mol Toxicol. 2007;21(5):265-72. 9. Chen CL, etal., Br J Cancer. 2007 Feb 26;96(4):591-9. 10. Chong ZZ, etal., J Cereb Blood Flow Metab 2003 Mar;23(3):320-30. 11. Duan Z, etal., Mol Pharmacol. 2007 Nov;72(5):1137-45. Epub 2007 Aug 3. 12. Fujinaka Y, etal., J Biol Chem. 2007 Oct 19;282(42):30707-17. Epub 2007 Aug 29. 13. GOA data from the GO Consortium 14. Gobe G, etal., Cancer Invest. 2002;20(3):324-32. 15. Hameed DA, etal., Urology. 2008 Mar 14;. 16. Hsu SY, etal., Proc Natl Acad Sci U S A 1997 Nov 11;94(23):12401-6. 17. Imaizumi K, etal., J Biol Chem 1999 Mar 19;274(12):7975-81. 18. Itoh T, etal., J Neurochem 2003 Jun;85(6):1500-12. 19. Kaufmann T, etal., J Cell Biol 2003 Jan 6;160(1):53-64. 20. KEGG 21. Kim HJ, etal., J Nutr Biochem. 2007 Sep 12;. 22. Kim HS, etal., Vis Neurosci. 2007 Mar-Apr;24(2):127-39. 23. Koh PO Life Sci. 2007 Sep 8;81(13):1079-84. Epub 2007 Aug 25. 24. Kosten TA, etal., Neuropsychopharmacology. 2007 Aug 15;. 25. Kwon Y and Magnuson BA, Exp Gerontol. 2007 Dec;42(12):1154-61. Epub 2007 Oct 10. 26. Lindsten T, etal., Neuroscientist. 2005 Feb;11(1):10-5. 27. Lovekamp-Swan T, etal., Neuroscience. 2007 Sep 7;148(3):644-52. Epub 2007 Jul 17. 28. MGD data from the GO Consortium 29. Nair VD, etal., J Biol Chem. 2006 Dec 22;281(51):39550-60. Epub 2006 Oct 23. 30. NCBI rat LocusLink and RefSeq merged data July 26, 2002 31. Nishimura Y, etal., Int J Immunopathol Pharmacol. 2007 Oct-Dec;20(4):661-7. 32. Onoue S, etal., FEBS J. 2008 Nov;275(22):5542-51. 33. Parborell F, etal., Biol Reprod. 2007 Nov 7;. 34. Pillai A, etal., Neuropsychopharmacology. 2007 Sep 5;. 35. Pipeline to import KEGG annotations from KEGG into RGD Pathway Ontology 36. Pipeline to import Pathway Interaction Database annotations from NCI into RGD 37. RGD automated data pipeline 38. RGD automated import pipeline for gene-chemical interactions 39. Sebastiani V, etal., Anticancer Res. 2006 Jul-Aug;26(4B):2983-7. 40. Shiraiwa N, etal., J Biol Chem 1996 May 31;271(22):13258-65. 41. Sorensen RB, etal., Cancer Immunol Immunother. 2007 Apr;56(4):527-33. Epub 2006 Jul 19. 42. Suzuki YJ, etal., Am J Respir Cell Mol Biol. 2007 Jun;36(6):678-87. Epub 2007 Feb 1. 43. Valks DM, etal., J Biol Chem 2003 Jul 11;278(28):25542-7. 44. Wang R, etal., Cancer Chemother Pharmacol. 2007 Jul 26;. 45. Wortham NC, etal., Fertil Steril. 2006 Oct;86(4):961-71. Epub 2006 Sep 7. 46. Yamanaka M, etal., J Urol. 2002 Nov;168(5):2296-300. References - uncurated PubMed 11721745   12394778   12477932   12496370   12785016   12967636   14532118   14676192   14999001   15121179   15149850   15545017   15574729   15596800   15720830   16085054   16111822   16133871   16205321   16301318   16428456   16603546   16723699   16815550   17132701   17600519   17644076   18053090   18163394   18221257   18250306   18347331   18497705   18923682   18980715   19082728   19339209   19862336   19885947   19938943   20106970   20457187   20499358   21308783   21710144   21740920   21861389   21863631   21926988   22292018   22366758   22424444   23015448   7828536   9346936   9731710 RGD Disease Portals Bcl2l1 has been annotated in the following RGD Disease Portals. Biological Process Cancer Diseases Cancer Pathways Cardiovascular Diseases Cardiovascular Pathways Diabetes Diseases Diabetes Pathways Immune and Inflammatory Pathways Neurological Diseases Neurological Pathways Obesity Diseases Obesity Pathways Respiratory Pathways Genomics Candidate Gene Status Bcl2l1 is a candidate Gene for Eau4 Comparative Map Data Bcl2l1   (Rattus norvegicus) Map Chr Position Strand Source Rat Cytogenetic Map 3 q41.2   NCBI RGSC Genome Assembly v5.0 3 154,662,586 - 154,716,802 - NCBI RGSC Genome Assembly v3.4 3 143,129,087 - 143,180,199 - NCBI Rat Celera Assembly 3 140,002,906 - 140,053,959 - NCBI Genome Assembly 3.1 3 143,082,602 - 143,084,431 - NCBI BCL2L1   (Homo sapiens) Map Chr Position Strand Source Human Alternate Assembly CHM1_1 20 30,265,445 - 30,323,807 - NCBI Human Genome Assembly HuRef 20 27,040,965 - 27,099,720 - NCBI Human Genome Assembly GRCh37 20 30,252,261 - 30,310,656 - NCBI Human Genome Assembly Build 36 20 29,715,922 - 29,774,317 - NCBI Human Cytogenetic Map 20 q11.21   NCBI Human Genome Assembly 20 29,715,923 - 29,774,317   NCBI Bcl2l1   (Mus musculus) Map Chr Position Strand Source Mouse Genome Assembly GRCm38 2 152,780,668 - 152,831,682 - NCBI Mouse cM Map 2 75.41   NCBI Mouse Celera Assembly 2 158,596,643 - 158,647,694 - NCBI Mouse Genome Assembly Build 37 2 152,606,404 - 152,657,418 - NCBI Mouse Genome Assembly Build 36.1 2 152,606,404 - 152,657,418 - NCBI Mouse Cytogenetic Map 2 H1   NCBI Position Markers D3Got106   Map Chr Position Strand Source Rat Cytogenetic Map 3 q41.2   UniSTS RGSC Genome Assembly v5.0 3 154,694,410 - 154,694,542   UniSTS RGSC Genome Assembly v3.4 3 143,157,805 - 143,157,937   UniSTS RGSC Genome Assembly v3.4 3 143,157,804 - 143,157,937   RGD Rat Celera Assembly 3 140,031,529 - 140,031,661   UniSTS Genome Assembly 3.1 3 143,063,427 - 143,063,559   RGD RH 3.4 3 1253.4   RGD RH 3.4 3 1253.4   UniSTS RH 2.0 3 852.1   RGD BM383754   Map Chr Position Strand Source Rat Cytogenetic Map 3 q41.2   UniSTS Rat Cytogenetic Map 1 q32   UniSTS RGSC Genome Assembly v5.0 3 154,663,616 - 154,663,793   UniSTS RGSC Genome Assembly v5.0 1 173,950,019 - 173,950,196   UniSTS RGSC Genome Assembly v3.4 3 143,130,117 - 143,130,294   UniSTS RGSC Genome Assembly v3.4 1 160,253,614 - 160,253,791   UniSTS Rat Celera Assembly 3 140,003,936 - 140,004,113   UniSTS Rat Celera Assembly 1 155,108,435 - 155,108,612   UniSTS RH 3.4 1 1288.3   UniSTS PMC196230P1   Map Chr Position Strand Source Rat Cytogenetic Map 1 q32   UniSTS Rat Cytogenetic Map 3 q41.2   UniSTS RGSC Genome Assembly v5.0 1 173,950,452 - 173,950,987   UniSTS RGSC Genome Assembly v3.4 1 160,254,047 - 160,254,582   UniSTS Rat Celera Assembly 1 155,108,868 - 155,109,403   UniSTS PMC316415P1   Map Chr Position Strand Source Rat Cytogenetic Map 1 q32   UniSTS Rat Cytogenetic Map 3 q41.2   UniSTS RGSC Genome Assembly v5.0 1 173,950,476 - 173,950,699   UniSTS RGSC Genome Assembly v3.4 1 160,254,071 - 160,254,294   UniSTS Rat Celera Assembly 1 155,108,892 - 155,109,115   UniSTS PMC123054P2   Map Chr Position Strand Source Rat Cytogenetic Map 1 q32   UniSTS Rat Cytogenetic Map 3 q41.2   UniSTS RGSC Genome Assembly v5.0 3 154,714,843 - 154,715,261   UniSTS RGSC Genome Assembly v5.0 1 173,950,662 - 173,951,080   UniSTS RGSC Genome Assembly v3.4 3 143,178,240 - 143,178,658   UniSTS RGSC Genome Assembly v3.4 1 160,254,257 - 160,254,675   UniSTS Rat Celera Assembly 3 140,052,000 - 140,052,418   UniSTS Rat Celera Assembly 1 155,109,078 - 155,109,496   UniSTS PMC20354P5   Map Chr Position Strand Source Rat Cytogenetic Map 3 q41.2   UniSTS RGSC Genome Assembly v5.0 3 154,714,664 - 154,714,920   UniSTS RGSC Genome Assembly v3.4 3 143,178,061 - 143,178,317   UniSTS Rat Celera Assembly 3 140,051,821 - 140,052,077   UniSTS PMC262691P2   Map Chr Position Strand Source Rat Cytogenetic Map 3 q41.2   UniSTS RGSC Genome Assembly v5.0 3 154,714,625 - 154,714,806   UniSTS RGSC Genome Assembly v3.4 3 143,178,022 - 143,178,203   UniSTS Rat Celera Assembly 3 140,051,782 - 140,051,963   UniSTS UniSTS:224427   Map Chr Position Strand Source Rat Cytogenetic Map 1 q32   UniSTS Rat Cytogenetic Map 3 q41.2   UniSTS RGSC Genome Assembly v5.0 3 154,663,753 - 154,663,906   UniSTS RGSC Genome Assembly v5.0 1 173,950,156 - 173,950,309   UniSTS RGSC Genome Assembly v3.4 3 143,130,254 - 143,130,407   UniSTS RGSC Genome Assembly v3.4 1 160,253,751 - 160,253,904   UniSTS Rat Celera Assembly 3 140,004,073 - 140,004,226   UniSTS Rat Celera Assembly 1 155,108,572 - 155,108,725   UniSTS Bcl2l   Map Chr Position Strand Source Rat Cytogenetic Map 1 q32   UniSTS Rat Cytogenetic Map 3 q41.2   UniSTS RGSC Genome Assembly v5.0 1 173,950,449 - 173,951,023   UniSTS RGSC Genome Assembly v3.4 1 160,254,044 - 160,254,618   UniSTS Rat Celera Assembly 1 155,108,865 - 155,109,439   UniSTS Bcl2l1   Map Chr Position Strand Source Rat Cytogenetic Map 1 q32   UniSTS Rat Cytogenetic Map 3 q41.2   UniSTS RGSC Genome Assembly v5.0 1 173,950,591 - 173,950,959   UniSTS Rat Celera Assembly 1 155,109,007 - 155,109,375   UniSTS QTLs in Region (RGSC Genome Assembly v3.4) The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer RGD ID Symbol Name LOD P Value Trait Sub Trait Chr Start Stop Species 2301970 Bw81 Body weight QTL 81 5.19 Body weight 3 39052756 158038027 Rat 2301971 Cm71 Cardiac mass QTL 71 4.63 Cardiac mass left ventricle 3 39052756 158038027 Rat 1559282 Emca5 Estrogen-induced mammary cancer QTL 5 3.9 Mammary tumor susceptibility estradiol-induced 3 41054012 171063335 Rat 2292591 Esta4 Estrogen-induced thymic atrophy QTL 4 Gland mass thymus 3 44551252 149496698 Rat 1581568 Rf53 Renal function QTL 53 Renal function urine protein level 3 53876762 163443738 Rat 1581546 Pur13 Proteinuria QTL 13 2.93 .0335 Renal function urine protein level 3 76620970 148642985 Rat 631841 Niddm39 Non-insulin dependent diabetes mellitus QTL 39 3.36 Glucose level post-pancreatectomy 3 93894678 161985069 Rat 2293087 Iddm27 Insulin dependent diabetes mellitus QTL 27 2.37 Glucose level insulin-dependent 3 96506745 149496698 Rat 2312659 Slep7 Serum leptin concentration QTL 7 .001 Hormone level leptin 3 97523869 170016653 Rat 2312670 Bw94 Body weight QTL 94 .01 Body weight adiposity index 3 97523869 170016653 Rat 2312673 Scl63 Serum cholesterol level QTL 63 .001 Lipid level serum cholesterol 3 97523869 170016653 Rat 2302373 Gluco39 Glucose level QTL 39 5.01 Glucose level 3 97524000 163778606 Rat 1300161 Rf10 Renal function QTL 10 3.57 Renal function hypertension related renal vascular resistance 3 101298208 163335184 Rat 619618 Rf3 Renal disease susceptibility QTL 3 6.5 .001 Renal function urine albumin excretion rate to body weight ratio 3 108688653 153688653 Rat 1578754 Stresp16 Stress response QTL 16 4 .001 Stress response plasma renin activity 3 113902006 158902006 Rat 1576306 Schws3 Schwannoma susceptibility QTL 3 .001 Neural tumor susceptibility tumor incidence 3 120714678 165714678 Rat 1300173 Rf11 Renal function QTL 11 3.38 Renal function hypertension related renal blood flow 3 121618954 147990731 Rat 1300159 Kidm4 Kidney mass QTL 4 3.83 Kidney mass hypertension related 3 121618954 159769019 Rat 1598877 Bp285 Blood pressure QTL 285 1.5 .03 Blood pressure systolic 3 122541511 167541511 Rat 631541 Bp81 Blood pressure QTL 81 4 Blood pressure systolic 3 124893448 171063335 Rat 2303620 Vencon4 Ventilatory control QTL 4 3.1 Ventilatory control hypoxic challenge 3 127988419 170016653 Rat 631673 Iddm13 Insulin dependent diabetes mellitus QTL 13 1.3 .663 Glucose level 3 131188558 163778754 Rat 1578653 Vnigr3 Vascular neointimal growth QTL 3 3.1 Vascular neointimal growth after injury blood vessel neointimal area 3 132947812 171063335 Rat 1578656 Vnigr2 Vascular neointimal growth QTL 2 4.2 Vascular neointimal growth after injury blood vessel lumen size 3 132947812 171063335 Rat 2298477 Eau4 Experimental allergic uveoretinitis QTL 4 .0011 Uvea inflammation 3 139485124 171063335 Rat 5686842 Rf59 Renal function QTL 59 Renal function urine protein level 3 141890118 149038578 Rat Sequence Nucleotide Sequences Nucleotide RefSeqs NM_001033670 (Get FASTA) Search GEO for Microarray Profiles   NM_001033671 (Get FASTA) Search GEO for Microarray Profiles   NM_001033672 (Get FASTA) Search GEO for Microarray Profiles   NM_031535 (Get FASTA) Search GEO for Microarray Profiles GenBank Nucleotide AABR06027077 (Get FASTA) Search GEO for Microarray Profiles   AABR06027078 (Get FASTA) Search GEO for Microarray Profiles   AABR06027079 (Get FASTA) Search GEO for Microarray Profiles   AAHX01025891 (Get FASTA) Search GEO for Microarray Profiles   AAHX01025892 (Get FASTA) Search GEO for Microarray Profiles   AAHX01025893 (Get FASTA) Search GEO for Microarray Profiles   AF136230 (Get FASTA) Search GEO for Microarray Profiles   AF279286 (Get FASTA) Search GEO for Microarray Profiles   AJ495801 (Get FASTA) Search GEO for Microarray Profiles   AY141038 (Get FASTA) Search GEO for Microarray Profiles   BC094213 (Get FASTA) Search GEO for Microarray Profiles   CH474050 (Get FASTA) Search GEO for Microarray Profiles   S76513 (Get FASTA) Search GEO for Microarray Profiles   S78284 (Get FASTA) Search GEO for Microarray Profiles   U34963 (Get FASTA) Search GEO for Microarray Profiles   U72349 (Get FASTA) Search GEO for Microarray Profiles   U72350 (Get FASTA) Search GEO for Microarray Profiles Reference Sequences RefSeq Acc Id: NM_001033670 RefSeq Status: VALIDATED Type: CODING Protein Acc Id: NP_001028842 Peptide Label: isoform 2 Position: Map Chr Position Strand Source RGSC Genome Assembly v5.0 3 154,662,586 - 154,716,802 - NCBI RGSC Genome Assembly v3.4 3 143,129,087 - 143,180,199 - RGD Rat Celera Assembly 3 140,002,906 - 140,053,959 - RGD RefSeq Acc Id: NM_001033671 RefSeq Status: VALIDATED Type: CODING Protein Acc Id: NP_001028843 Peptide Label: isoform 3 Position: Map Chr Position Strand Source RGSC Genome Assembly v5.0 3 154,662,586 - 154,716,802 - NCBI RGSC Genome Assembly v3.4 3 143,129,087 - 143,180,199 - RGD Rat Celera Assembly 3 140,002,906 - 140,053,959 - RGD RefSeq Acc Id: NM_001033672 RefSeq Status: VALIDATED Type: CODING Protein Acc Id: NP_001028844 Peptide Label: isoform 1 Position: Map Chr Position Strand Source RGSC Genome Assembly v5.0 3 154,662,586 - 154,716,802 - NCBI RGSC Genome Assembly v3.4 3 143,129,087 - 143,180,199 - RGD Rat Celera Assembly 3 140,002,906 - 140,053,959 - RGD RefSeq Acc Id: NM_031535 RefSeq Status: VALIDATED Type: CODING Protein Acc Id: NP_113723 Peptide Label: isoform 1 Position: Map Chr Position Strand Source RGSC Genome Assembly v5.0 3 154,662,586 - 154,716,802 - NCBI RGSC Genome Assembly v3.4 3 143,129,087 - 143,180,199 - RGD Rat Celera Assembly 3 140,002,906 - 140,053,959 - RGD Protein Sequences Protein RefSeqs NP_001028842 (Get FASTA)   NP_001028843 (Get FASTA)   NP_001028844 (Get FASTA)   NP_113723 (Get FASTA) GenBank Protein AAA77686 (Get FASTA)   AAB17352 (Get FASTA)   AAB17353 (Get FASTA)   AAC60701 (Get FASTA)   AAC60702 (Get FASTA)   AAD33683 (Get FASTA)   AAF81262 (Get FASTA)   AAH94213 (Get FASTA)   AAN17784 (Get FASTA)   CAD42238 (Get FASTA)   EDL86039 (Get FASTA)   EDL86042 (Get FASTA)   EDL86043 (Get FASTA)   P53563 (Get FASTA) Strain Variation Strain Sequence Variants ACI/Eur (MCW) Visual CSV TAB Printer Sequenced By: Medical College of Wisconsin (Dr. Howard Jacob) Platform: Illumina HiSeq 2000 Secondary Analysis: BWA v0.5.9-r16 and GATK v1.3-14 ACI/N (KNAW) Visual CSV TAB Printer Sequenced By: Royal Netherland Academy of Arts and Sciences (Dr. Edwin Cuppen) Max Delbruck Center for Molecular Medicine (Dr. Norbert Huebner) Platform: SOLID Secondary Analysis: SAP42 (Developed at RNAAS) Breeder: National Institutes of Health Grant Information: EURATRANS (HEALTH-F4-2010-241504) BN-Lx (ICL) Visual CSV TAB Printer Sequenced By: Royal Netherland Academy of Arts and Sciences (Dr. Edwin Cuppen) Imperial College London (Dr Timothy Aitman) Platform: SOLID Secondary Analysis: BWA, GATK, Samtools Breeder: Academy of Sciences of the Czech Republic (Dr.Michal Pravenec) Grant Information: MC-A654-5QB00 BN-Lx (KNAW) Visual CSV TAB Printer Sequenced By: Royal Netherland Academy of Arts and Sciences (Dr. Edwin Cuppen) Platform: SOLID Secondary Analysis: SAP42 (Developed at RNAAS) Breeder: Academy of Sciences of the Czech Republic (Dr.Michal Pravenec) Grant Information: EURATRANS (HEALTH-F4-2010-241504) BN/NHsdMcwi (KNAW) Visual CSV TAB Printer Sequenced By: Royal Netherland Academy of Arts and Sciences (Dr. Edwin Cuppen) Max Delbruck Center for Molecular Medicine (Dr. Norbert Huebner) Platform: SOLID Secondary Analysis: SAP42 (Developed at RNAAS) Breeder: Medical College of Wisconsin Grant Information: EURATRANS (HEALTH-F4-2010-241504) BN/SsN (KNAW) Visual CSV TAB Printer Sequenced By: Royal Netherland Academy of Arts and Sciences (Dr. Edwin Cuppen) Max Delbruck Center for Molecular Medicine (Dr. Norbert Huebner) Platform: SOLID Secondary Analysis: SAP42 (Developed at RNAAS) Breeder: National Institutes of Health Grant Information: EURATRANS (HEALTH-F4-2010-241504) Buf/N (KNAW) Visual CSV TAB Printer Sequenced By: Royal Netherland Academy of Arts and Sciences (Dr. Edwin Cuppen) Max Delbruck Center for Molecular Medicine (Dr. Norbert Huebner) Platform: SOLID Secondary Analysis: SAP42 (Developed at RNAAS) Breeder: National Institutes of Health Grant Information: EURATRANS (HEALTH-F4-2010-241504) COP/Crl (MCW & UW) Visual CSV TAB Printer Sequenced By: Medical College of Wisconsin (Dr. Howard Jacob) Univiersity of Wisconsin (Jim Shull) Platform: Illumina HiSeq 2000 Secondary Analysis: BWA v0.5.9-r16 and GATK v2.3-5 Breeder: Charles River Grant Information: NIH (CA77876) F344/N (KNAW) Visual CSV TAB Printer Sequenced By: Royal Netherland Academy of Arts and Sciences (Dr. Edwin Cuppen) Max Delbruck Center for Molecular Medicine (Dr. Norbert Huebner) Platform: SOLID Breeder: National Institutes of Health Grant Information: EURATRANS (HEALTH-F4-2010-241504) FHH/EurMcwi (MCW) Visual CSV TAB Printer Sequenced By: Medical College of Wisconsin (Dr. Howard Jacob) Platform: Illumina HiSeq 2000 Secondary Analysis: BWA v0.5.9-r16 and GATK v1.3-14 FHH/EurMcwi (MDC) Visual CSV TAB Printer Sequenced By: Max Delbruck Center for Molecular Medicine (Dr. Norbert Huebner) Platform: Illumina/Solexa, Genome Analyzer II Secondary Analysis: CASAVA Software v1.7 Breeder: Medical College of Wisconsin Grant Information: EURATRANS (HEALTH-F4-2010-241504) FHL/EurMcwi (MCW) Visual CSV TAB Printer Sequenced By: Medical College of Wisconsin (Dr. Howard Jacob) Platform: Illumina HiSeq 2000 Secondary Analysis: BWA v0.5.9-r16 and GATK v1.3-14 GH/OmrMcwi (MCW) Visual CSV TAB Printer Sequenced By: Medical College of Wisconsin (Dr. Howard Jacob) Platform: Illumina HiSeq 2000 Secondary Analysis: BWA v0.5.9-r16 and GATK v2.3-5 LE/Stm (KNAW) Visual CSV TAB Printer Sequenced By: Royal Netherland Academy of Arts and Sciences (Dr. Edwin Cuppen) Max Delbruck Center for Molecular Medicine (Dr. Norbert Huebner) Platform: SOLID Secondary Analysis: SAP42 (Developed at RNAAS) Breeder: Dr. Tadao Serikawa, Kyoto Japan. Grant Information: EURATRANS (HEALTH-F4-2010-241504) M520/N (KNAW) Visual CSV TAB Printer Sequenced By: Royal Netherland Academy of Arts and Sciences (Dr. Edwin Cuppen) Max Delbruck Center for Molecular Medicine (Dr. Norbert Huebner) Platform: SOLID Secondary Analysis: SAP42 (Developed at RNAAS) Breeder: National Institutes of Health Grant Information: EURATRANS (HEALTH-F4-2010-241504) MR/N (KNAW) Visual CSV TAB Printer Sequenced By: Royal Netherland Academy of Arts and Sciences (Dr. Edwin Cuppen) Max Delbruck Center for Molecular Medicine (Dr. Norbert Huebner) Platform: SOLID Breeder: National Institutes of Health Grant Information: EURATRANS (HEALTH-F4-2010-241504) SHR/Olalpcv (ICL) Visual CSV TAB Printer Sequenced By: Imperial College London (Dr Timothy Aitman) University of British Columbia (Dr. Steven Jones) Platform: Illumina Hi-seq 2000 and GAII Secondary Analysis: BWA, GATK Breeder: Institute of Physiology, Academy of Sciences of the Czech Republic, Prague Grant Information: LSHG-CT-2005-019015, HEALTH-F4-2010-241504 SHR/Olalpcv (KNAW) Visual CSV TAB Printer Sequenced By: Royal Netherland Academy of Arts and Sciences (Dr. Edwin Cuppen) Imperial College London (Dr Timothy Aitman) Platform: Illumina Secondary Analysis: GATK Grant Information: EURATRANS (HEALTH-F4-2010-241504) SHRSP/Gcrc (MDC) Visual CSV TAB Printer Sequenced By: Max Delbruch Center for Molecular Medicine (Dr. Norbert Huebner) Platform: Illumina/Solexa, Genome Analyzer II Secondary Analysis: CASAVA Software v1.7 Breeder: University of Glasgow, Anna Dominiczak Grant Information: EURATRANS (HEALTH-F4-2010-241504) SR/JrHsd (MCW) Visual CSV TAB Printer Sequenced By: Medical College of Wisconsin (Dr. Howard Jacob) Platform: Illumina HiSeq 2000 Secondary Analysis: BWA v0.5.9-r16 and GATK v1.3-14 Breeder: Harlan SS/JrHsdMcwi (MCW) Visual CSV TAB Printer Sequenced By: Medical College of Wisconsin (Dr. Howard Jacob) Platform: Illumina HiSeq 2000 Secondary Analysis: BWA v0.5.9-r16 and GATK v1.3-14 Grant Information: R01 HL089930 SS/JrHsdMcwi (MDC) Visual CSV TAB Printer Sequenced By: Max Delbruck Center for Molecular Medicine (Dr. Norbert Huebner) Platform: Illumina/Solexa, Genome Analyzer II Secondary Analysis: CASAVA Software v1.7 Breeder: Medical College of Wisconsin Grant Information: EURATRANS (HEALTH-F4-2010-241504) WKY/N (KNAW) Visual CSV TAB Printer Sequenced By: Royal Netherland Academy of Arts and Sciences (Dr. Edwin Cuppen) Max Delbruck Center for Molecular Medicine (Dr. Norbert Huebner) Platform: SOLID Secondary Analysis: SAP42 (Developed at RNAAS) Breeder: National Institutes of Health Grant Information: EURATRANS (HEALTH-F4-2010-241504) WN/N (KNAW) Visual CSV TAB Printer Sequenced By: Royal Netherland Academy of Arts and Sciences (Dr. Edwin Cuppen) Max Delbruck Center for Molecular Medicine (Dr. Norbert Huebner) Platform: SOLID Secondary Analysis: SAP42 (Developed at RNAAS) Breeder: National Institutes of Health Grant Information: EURATRANS (HEALTH-F4-2010-241504) Additional Information External Database Links Database Acc Id Source(s) Ensembl Genes ENSRNOG00000007946 ENTREZGENE, UniProtKB/Swiss-Prot Ensembl Protein ENSRNOP00000010762 ENTREZGENE, UniProtKB/Swiss-Prot   ENSRNOP00000043542 ENTREZGENE, UniProtKB/TrEMBL Ensembl Transcript ENSRNOT00000010762 ENTREZGENE, UniProtKB/Swiss-Prot   ENSRNOT00000047416 ENTREZGENE, UniProtKB/TrEMBL Entrez Gene 24888 ENTREZGENE Germonline ENSRNOG00000007946 UniProtKB/Swiss-Prot HomoloGene Group ID 7639 ENTREZGENE IMAGE_CLONE IMAGE:7314572 IMAGE-MGC_LOAD InterPro Apop_reg_BclX UniProtKB/Swiss-Prot   BCL2_apoptsis UniProtKB/Swiss-Prot   Bcl2_BH1_motif_CS UniProtKB/Swiss-Prot   Bcl2_BH2_motif_CS UniProtKB/Swiss-Prot   Bcl2_BH3_motif_CS UniProtKB/Swiss-Prot   Bcl2_BH4 UniProtKB/Swiss-Prot   Bcl2_BH4_motif_CS UniProtKB/Swiss-Prot   Bcl2_reg UniProtKB/Swiss-Prot   Blc2_fam UniProtKB/Swiss-Prot IPI IPI00211135 UniProtKB/Swiss-Prot   IPI00231893 UniProtKB/Swiss-Prot   IPI00231894 UniProtKB/Swiss-Prot KEGG Report rno:24888 ENTREZGENE, UniProtKB/Swiss-Prot MGC_CLONE MGC:105402 IMAGE-MGC_LOAD PANTHER PTHR11256 UniProtKB/Swiss-Prot   PTHR11256:SF12 UniProtKB/Swiss-Prot Pfam Bcl-2 UniProtKB/Swiss-Prot   BH4 UniProtKB/Swiss-Prot PRINTS APOPREGBCLX UniProtKB/Swiss-Prot   BCL2FAMILY UniProtKB/Swiss-Prot PROSITE BCL2_FAMILY UniProtKB/Swiss-Prot   BH1 UniProtKB/Swiss-Prot   BH2 UniProtKB/Swiss-Prot   BH3 UniProtKB/Swiss-Prot   BH4_1 UniProtKB/Swiss-Prot   BH4_2 UniProtKB/Swiss-Prot SMART BH4 UniProtKB/Swiss-Prot TIGRFAMs bcl-2 UniProtKB/Swiss-Prot UniGene Rn.10323 ENTREZGENE UniProt B2CL1_RAT UniProtKB/Swiss-Prot   Q548R7_RAT UniProtKB/TrEMBL   Q7TS62_RAT UniProtKB/TrEMBL   Q9WUI5_RAT UniProtKB/TrEMBL Nomenclature History Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status 2003-04-09 Bcl2l1  Bcl2-like 1  Bcl2l  B cell lymphoma 2 like  Symbol and Name updated 2574 APPROVED 2002-06-10 Bcl2l  B cell lymphoma 2 like      Symbol and Name status set to approved 1490 APPROVED RGD Curation Notes Note Type Note Reference gene_cellular_localization localized to the mitochondrial outer membrane 631757 gene_cellular_localization integral membrane protein localized to the mitochondrial membrane and nuclear envelope 628531 gene_expression expressed in the embryonic and adult neurons of the CNS 628531 gene_function anti-apoptotic factor 631757 gene_process involved in protecting cells from apoptosis and in controlling mitochondrial membrane permeability 631757 gene_process prevents neuronal apoptosis by blocking cytochrome c release 628531 gene_process may inhibit staurosporin induced neuronal apoptosis 628531 gene_product member of the anti-apoptotic Bcl-2 family 628531

More on Bcl2l1 Entrez Gene Ensembl Gene Genome Browser NCBI Map Viewer Vista Vista + UCSC RGD Object Information RGD ID: 2200 Created: 2000-05-25 Species: Rattus norvegicus Last Modified: 2013-04-16 Status: ACTIVE